<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006732</article-id><article-id pub-id-type="pmc">PMC11860707</article-id><article-id pub-id-type="doi">10.3390/vaccines13020185</article-id><article-id pub-id-type="publisher-id">vaccines-13-00185</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Current Development of Therapeutic Vaccines in Lung Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Flores Banda</surname><given-names>Jesus Salvador</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gangane</surname><given-names>Sanjana</given-names></name></contrib><contrib contrib-type="author"><name><surname>Raza</surname><given-names>Fatima</given-names></name></contrib><contrib contrib-type="author"><name><surname>Massarelli</surname><given-names>Erminia</given-names></name><xref rid="c1-vaccines-13-00185" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>He</surname><given-names>Xingxing</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Jin</surname><given-names>Honglin</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-13-00185">Department of Medicine, University of Texas at Tyler School of Medicine, 11937 US Hwy 271, Tyler, TX 75799, USA; <email>jesus.floresbanda@uttyler.edu</email> (J.S.F.B.); <email>sanjana.gangane@uttyler.edu</email> (S.G.); <email>fatima.raza@uttyler.edu</email> (F.R.)</aff><author-notes><corresp id="c1-vaccines-13-00185"><label>*</label>Correspondence: <email>erminia.massarelli@uttyler.edu</email>; Tel.: +1-903-877-7902</corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>13</volume><issue>2</issue><elocation-id>185</elocation-id><history><date date-type="received"><day>05</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>02</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>10</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Cancer vaccines have a potential to change the current landscape of immunotherapy research and development. They target and neutralize specific tumor cells by utilizing the body&#x02019;s own immune system which offers a promising modality in treating various cancers including lung cancer. Historically, prior vaccination approaches specifically towards lung cancer have posed several challenges but also potential with early phase I/II trials showing improved overall survival. With better understanding of the body&#x02019;s immune system as well as advancements in vaccine development, the use of vaccines to target lung cancer cells in both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) has shown promise but also challenges in the setting of advanced stage cancers, tumor resistance mechanisms, immune evasion, and tumor heterogeneity. The proposed solution is to enroll patients in the early stages of the disease, rather than waiting until progression occurs. Additionally, future efforts will focus on the targeted identification of specific and novel tumor neo-antigens. This review offers discussion and analysis of both completed and ongoing trials utilizing different strategies for vaccine development in relation to treating lung cancer as well as current challenges faced.</p></abstract><kwd-group><kwd>lung cancer</kwd><kwd>small cell lung cancer</kwd><kwd>non-small cell lung cancer</kwd><kwd>therapeutic cancer vaccines</kwd><kwd>clinical trials</kwd></kwd-group><funding-group><funding-statement>This review did not receive any external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-13-00185"><title>1. Introduction</title><p>Lung cancer constitutes a significant global health challenge, ranking as the second most frequently diagnosed cancer and serving as the leading cause of cancer-related mortality in the United States [<xref rid="B1-vaccines-13-00185" ref-type="bibr">1</xref>]. While conventional treatment options often exhibit limited efficacy, cancer immunotherapy has emerged as a promising therapeutic avenue [<xref rid="B2-vaccines-13-00185" ref-type="bibr">2</xref>]. In this context, vaccines represent an essential strategy for activating the adaptive immune system against tumor cells [<xref rid="B3-vaccines-13-00185" ref-type="bibr">3</xref>]. Currently, there are four FDA-approved vaccines for cancer: sipuleucel-T for prostate cancer, bacillus Calmette-Gu&#x000e9;rin and nadofaragene firadonevec for bladder cancer, and T-VEC for melanoma, but no vaccines have been approved for lung cancer [<xref rid="B4-vaccines-13-00185" ref-type="bibr">4</xref>]. This article provides a comprehensive review of the latest advancements in therapeutic cancer vaccines specifically designed for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). By exploring recent clinical findings and ongoing trials, this article seeks to shed light on the potential of these vaccines to improve outcomes for patients diagnosed with lung cancer [<xref rid="B5-vaccines-13-00185" ref-type="bibr">5</xref>].</p></sec><sec id="sec2-vaccines-13-00185"><title>2. NSCLC Therapeutic Vaccines</title><p>NSCLC is categorized into three primary histological subtypes: lung adenocarcinoma, squamous cell carcinoma, and large cell carcinoma [<xref rid="B6-vaccines-13-00185" ref-type="bibr">6</xref>]. It is the most common form of lung cancer, but the complexity of this disease is further exacerbated by considerable genetic heterogeneity [<xref rid="B7-vaccines-13-00185" ref-type="bibr">7</xref>]. Unfortunately, NSCLC is associated with a challenging prognosis, evidenced by a five-year survival rate of only 15.9%, which has seen some improvements over recent decades due to approvals of immunotherapy and targeted therapies against specific genes including epidermal growth factor receptor (EGFR) and echinoderm microtubule-associated protein-like 4 (EML-4)-anaplastic lymphoma kinase (ALK), which have shown greater treatment response and increased survival in early stage and metastatic setting. Significant discoveries have led to targeted therapy being used in NSCLC with other specific gene alterations in the metastatic disease: KRASG12C, BRAFV600E, MET exon 14 skipping gene alterations, ROS1 fusions, RET fusions, and NTRK1-3 fusions [<xref rid="B8-vaccines-13-00185" ref-type="bibr">8</xref>]. For patients lacking actionable gene alterations, immune checkpoint inhibitors (ICIs) play a crucial role in treatment alone or in combination with platinum-based chemotherapy. Currently, surgery is potentially the most curative option for early-stage disease either with or without adjuvant, neoadjuvant, or perioperative chemotherapy in combination with immunotherapy or targeted therapy [<xref rid="B9-vaccines-13-00185" ref-type="bibr">9</xref>]. Additionally, tumor vaccines are emerging as a significant advancement in cancer therapies [<xref rid="B10-vaccines-13-00185" ref-type="bibr">10</xref>]. These interventions are part of a broader array of innovative immunotherapy strategies aimed at enhancing the immune system&#x02019;s response to cancer cells.</p><sec id="sec2dot1-vaccines-13-00185"><title>2.1. Peptide/Protein Vaccines</title><p>A peptide vaccine represents a promising therapeutic strategy that employs synthesized protein fragments, referred to as peptides, to elicit targeted immune responses [<xref rid="B11-vaccines-13-00185" ref-type="bibr">11</xref>]. This approach involves the administration of tumor antigen-derived peptides in a personalized manner, effectively directing the immune system toward specific tumor antigens [<xref rid="B12-vaccines-13-00185" ref-type="bibr">12</xref>], as shown in <xref rid="vaccines-13-00185-f001" ref-type="fig">Figure 1</xref>. One advantage of peptide and protein vaccines is that they can be administered intravenously, intradermally, or intramuscularly with some tolerable side effects, as stated in <xref rid="vaccines-13-00185-t001" ref-type="table">Table 1</xref>.</p><sec id="sec2dot1dot1-vaccines-13-00185"><title>2.1.1. Epidermal Growth Factor (EGF)</title><p>EGF is a signaling molecule that binds to and activates the EGFR on cell surfaces to promote proliferation and migration, but dysregulation of this process can contribute to many different cancers [<xref rid="B13-vaccines-13-00185" ref-type="bibr">13</xref>]. The vaccine utilizes a laboratory-engineered EGF protein to trigger an immune response, and this response results in the production of antibodies that target the body&#x02019;s own EGF molecules, leading to reduced EGF levels in the bloodstream and diminished interaction with its receptor, EGFR [<xref rid="B14-vaccines-13-00185" ref-type="bibr">14</xref>]. The CIMAvax-EGF vaccine has received approval as a maintenance therapy for patients with stage IIIB/IV NSCLC who exhibit a partial response (PR) or stable disease (SD) following first-line chemotherapy in various Latin American countries. The treatment demonstrates significant benefits for patients exhibiting high serum EGF concentrations, specifically those exceeding 870 pg/mL [<xref rid="B15-vaccines-13-00185" ref-type="bibr">15</xref>]. Clinical findings indicate that this vaccine is associated with a median overall survival (OS) of 14.6 months (95% CI 10.6&#x02013;18.8) and a progression-free survival (PFS) of 8.16 months (95% CI 4.9&#x02013;11.3) [<xref rid="B16-vaccines-13-00185" ref-type="bibr">16</xref>]. The efficacy of this mechanism can be further improved when combined with ICIs, which facilitate the release of inhibitory signals on T cells, leading to more effective therapeutic outcomes [<xref rid="B17-vaccines-13-00185" ref-type="bibr">17</xref>]. The ongoing phase II clinical trial (NCT02955290) evaluates the efficacy of CIMAvax-EGF in combination with nivolumab in the American population. Preliminary results indicate OS of 11.9 months (90% CI 8.0&#x02013;23.9), which appears to be a numerical improvement compared to historical cohorts receiving nivolumab therapy. Patients who are EGFR/ALK/KRAS wild-type experienced more favorable outcomes, as indicated by a median OS of 31.7 months (90% CI 5.9, NR) and a 3-year survival rate of 50% (90% CI 24, 71). In contrast, KRAS-mutated patients had a median OS of only 10.1 months (90% CI 6.5, 12.1) and a 3-year survival rate of 0% (90% CI 1, 41). Additionally, research shows that patients with PD-L1 expression levels of 1% or higher had better outcomes, with a 3-year OS rate of 38% (90% CI 12, 63) and a 3-year PFS rate of 38% (90% CI 12, 63). Conversely, patients without PD-L1 expression had lower rates, reporting a 3-year OS of 23% (90% CI 8, 44) and a 3-year PFS of just 8% (90% CI 1, 25) [<xref rid="B18-vaccines-13-00185" ref-type="bibr">18</xref>].</p></sec><sec id="sec2dot1dot2-vaccines-13-00185"><title>2.1.2. Melanoma Antigen Family A, 3 (MAGE-A3)</title><p>MAGE-A3 is a tumor-specific shared antigen protein exclusively associated with neoplastic tissues [<xref rid="B19-vaccines-13-00185" ref-type="bibr">19</xref>]. It is not expressed in normal adult tissues, apart from testicular cells, which do not present the antigen to the immune system [<xref rid="B20-vaccines-13-00185" ref-type="bibr">20</xref>]. The expression of MAGE-A3 has been observed in various cancer types, including melanoma (74%), bladder cancer (35%), head and neck cancers (49%), and NSCLC (35&#x02013;50%) [<xref rid="B21-vaccines-13-00185" ref-type="bibr">21</xref>]. The mechanism of action of the vaccine involves dendritic cells (DCs) capturing antigens and processing them into peptides that bind to HLA class I and II molecules. This interaction activates CD8+ and CD4+ lymphocytes, triggering an immune response against cancer cells [<xref rid="B22-vaccines-13-00185" ref-type="bibr">22</xref>]. The phase III clinical trial, referred to as the MAGRIT study (NCT00480025), has been terminated due to the Independent Data Monitoring Committee&#x02019;s assessment that the study product did not demonstrate sufficient effectiveness [<xref rid="B23-vaccines-13-00185" ref-type="bibr">23</xref>]. However, preliminary findings from the early phase II clinical trial suggested that patients with MAGE-A3 positive resected NSCLC at stages IB, II, or IIIA experienced a 43% reduction in the relative risk of relapse compared to those receiving a placebo [<xref rid="B24-vaccines-13-00185" ref-type="bibr">24</xref>].</p></sec><sec id="sec2dot1dot3-vaccines-13-00185"><title>2.1.3. New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1)</title><p>NY-ESO-1 is a well-recognized cancer/testis antigen (CTA) known for its unique expression and immunological characteristics [<xref rid="B25-vaccines-13-00185" ref-type="bibr">25</xref>]. It has become a key target for cancer immunotherapy, especially for solid tumors like neuroblastoma (82%), synovial sarcoma (80%), melanoma (46%), cervical cancer (45%), and epithelial ovarian cancer (43%), with the vaccine primarily stimulating both cellular and antibody-based immune responses [<xref rid="B26-vaccines-13-00185" ref-type="bibr">26</xref>,<xref rid="B27-vaccines-13-00185" ref-type="bibr">27</xref>]. Two clinical trials assessing this vaccine, namely LV305 (NCT02122861) and G305 (NCT02015416), intended to recruit patients with solid tumors, including NSCLC. However, only one patient with NSCLC was enrolled in the LV305 trial and discontinued treatment due to disease progression [<xref rid="B28-vaccines-13-00185" ref-type="bibr">28</xref>]. In the latter trial G305, patients with NSCLC have still to be enrolled [<xref rid="B29-vaccines-13-00185" ref-type="bibr">29</xref>].</p></sec><sec id="sec2dot1dot4-vaccines-13-00185"><title>2.1.4. Mucin 1 (MUC1)</title><p>Mucin 1 (MUC1) is a transmembrane protein characterized by extensive glycosylation, which plays a crucial role in various physiological functions, including protection and lubrication within the body [<xref rid="B30-vaccines-13-00185" ref-type="bibr">30</xref>]. In cancer cells, however, MUC1 exhibits abnormal glycosylation patterns and increased expression levels, thereby altering its role from a protective molecule to one that facilitates tumor progression [<xref rid="B31-vaccines-13-00185" ref-type="bibr">31</xref>]. A promising therapeutic vaccine, L-BLP25, commercially also known as tecemotide, has been developed as an immunotherapy for NSCLC, specifically targeting MUC1 to enhance treatment efficacy [<xref rid="B32-vaccines-13-00185" ref-type="bibr">32</xref>]. The phase I clinical trial (NCT01731587), which focused on patients with unresectable stage III NSCLC demonstrating SD following primary chemoradiotherapy, has been withdrawn because the objectives of the trial were found to not be suitable for the development of the vaccine [<xref rid="B33-vaccines-13-00185" ref-type="bibr">33</xref>]. In contrast, the phase IIb clinical trial (NCT00828009) assessed the efficacy of tecemotide in combination with bevacizumab as maintenance therapy for patients with unresectable stage IIIA and IIIB non-squamous NSCLC following definitive chemoradiation. This trial reported OS of 42.7 months (95% CI 21.7&#x02013;63.3) and PFS of 14.9 months (95% CI 11.0&#x02013;20.9) [<xref rid="B34-vaccines-13-00185" ref-type="bibr">34</xref>]. Conversely, the findings of the phase III START trial (NCT00409188), which evaluated the vaccine alone, indicated no significant difference in OS between the vaccinated patients and the control group, with median survival durations of 25.6 months (95% CI 22.5&#x02013;29.2) and 22.3 months (95% 19.6&#x02013;25.5), respectively [<xref rid="B35-vaccines-13-00185" ref-type="bibr">35</xref>]. Subsequent trials, including the START2 trial (NCT02049151) which aimed to evaluate tecemotide in patients with unresectable stage III NSCLC as well as the INSPIRE trial (NCT01015443), which focused primarily on the Asian population, both were discontinued prematurely [<xref rid="B36-vaccines-13-00185" ref-type="bibr">36</xref>,<xref rid="B37-vaccines-13-00185" ref-type="bibr">37</xref>]. This decision was made by the sponsor due to the studies not meeting the primary endpoint OS as well secondary endpoints which were PFS, time to progression, and time to treatment failure [<xref rid="B38-vaccines-13-00185" ref-type="bibr">38</xref>].</p></sec></sec><sec id="sec2dot2-vaccines-13-00185"><title>2.2. DNA Vaccines</title><p>A DNA vaccine is an innovative approach to immunization that utilizes genetic material in the form of engineered plasmids (<xref rid="vaccines-13-00185-f002" ref-type="fig">Figure 2</xref>). These plasmids carry instructions for producing specific target proteins that stimulate immune responses [<xref rid="B39-vaccines-13-00185" ref-type="bibr">39</xref>]. One of the major advantages of DNA vaccines is their ability to engage multiple components of the immune system simultaneously. They present their encoded antigens through both MHC class I and II pathways, leading to the activation of CD8 cytotoxic T cells and CD4 helper T cells, while also stimulating antibody-based (humoral) immune responses [<xref rid="B40-vaccines-13-00185" ref-type="bibr">40</xref>]. However, no current clinical trials are recruiting patients with NSCLC [<xref rid="B41-vaccines-13-00185" ref-type="bibr">41</xref>].</p></sec><sec id="sec2dot3-vaccines-13-00185"><title>2.3. Vector Vaccines</title><p>A vector vaccine represents a form of genetic vaccination that employs a modified virus as a delivery mechanism to introduce genetic material encoding disease-specific antigens into human cells [<xref rid="B42-vaccines-13-00185" ref-type="bibr">42</xref>] (<xref rid="vaccines-13-00185-f003" ref-type="fig">Figure 3</xref>). Utilizing the inherent capability of viruses to transport genetic material into cells, these vaccines facilitate the production of specific antigens that stimulate immune responses [<xref rid="B43-vaccines-13-00185" ref-type="bibr">43</xref>]. The main advantage of vector vaccines is correlated to their ability to elicit both cellular and humoral immune responses, to overcome the need for additional adjuvants [<xref rid="B44-vaccines-13-00185" ref-type="bibr">44</xref>]. Another advantage of vector vaccines is that they can be administered either intravenously or intramuscularly, and the reported side effects are manageable, as stated in <xref rid="vaccines-13-00185-t002" ref-type="table">Table 2</xref>. Several clinical trials are ongoing to evaluate the efficacy of vector vaccines (<xref rid="vaccines-13-00185-t002" ref-type="table">Table 2</xref>). A phase II clinical trial (NCT03353675) enrolled patients with advanced, untreated NSCLC with less than 50% PD-L1 expression after first-line chemotherapy; participants received the vector vaccine MVA-MUC1-IL2, also named as TG410, which includes a modified virus carrying the MUC1 protein and interleukin-2, alongside nivolumab, but the results have not been reported yet [<xref rid="B45-vaccines-13-00185" ref-type="bibr">45</xref>]. A phase II European clinical trial assessed the effects of concurrent chemotherapy and TG410 in two arms. Arm 1 received chemotherapy plus the vaccine, while arm 2 started with the vaccine alone and later added chemotherapy upon disease progression. Arm 1 showed a PR in 13 out of 37 patients with stage III/IV NSCLC, based on Response Evaluation Criteria in Solid Tumors (RECIST) criteria, while arm 2 did not meet criteria for proceeding to the second state [<xref rid="B46-vaccines-13-00185" ref-type="bibr">46</xref>]. A new vector vaccine composed with semi-allogeneic fibroblasts transfected with autologous tumor-derived DNA was about to be evaluated in the clinical trial (NCT00793208), but the study was terminated due to low enrollment [<xref rid="B47-vaccines-13-00185" ref-type="bibr">47</xref>]. The MG1-MAGEA3 with Ad-MAGEA3 vector vaccine combines an engineered oncolytic Maraba virus that expresses MAGE-A3 with transgenic MAGE3 adenovirus vaccines [<xref rid="B48-vaccines-13-00185" ref-type="bibr">48</xref>,<xref rid="B49-vaccines-13-00185" ref-type="bibr">49</xref>]. The phase II clinical trial (NCT02879760) assessed the efficacy of a vaccine combined with pembrolizumab in patients with squamous and non-squamous NSCLC who had completed at least one cycle of platinum-based chemotherapy and/or at least one treatment with PD-1 or PDL-1 antibody-targeted therapy. Results from the trial have not yet been reported [<xref rid="B50-vaccines-13-00185" ref-type="bibr">50</xref>]. An active phase I clinical trial (NCT02285816) is assessing MG1-MAGEA3 with and without Ad-MAGEA3 in patients with incurable, advanced, or metastatic MAGE-A3-expressing solid tumors, including NSCLC (adenocarcinoma and squamous cell carcinoma), although results have not yet been reported [<xref rid="B51-vaccines-13-00185" ref-type="bibr">51</xref>]. Pitfalls of viral-based cancer vaccines are related to risk of side effects from the viral vector, such as inflammation and allergic reactions. In addition, effectiveness of these vaccines can be reduced by pre-existent immunity to the virus used to construct the vaccine.</p></sec><sec id="sec2dot4-vaccines-13-00185"><title>2.4. Dendritic Cell (DC) Vaccines</title><p>A DC vaccine is an advanced immunotherapy that utilizes the unique ability of DCs to activate CD4+ and CD8+ T cells, enhancing the immune response to tumor-specific antigens [<xref rid="B52-vaccines-13-00185" ref-type="bibr">52</xref>] (<xref rid="vaccines-13-00185-f004" ref-type="fig">Figure 4</xref>). This approach addresses the challenge of inadequate antigen presentation in cancer patients [<xref rid="B53-vaccines-13-00185" ref-type="bibr">53</xref>]. The process typically involves isolating DCs from the patient&#x02019;s monocytes or CD34+ cells, loading them with tumor antigens, and activating them with toll-like receptor ligands or cytokines, then the activated DCs are then reintroduced into the patient to stimulate a robust immune response against the cancer [<xref rid="B54-vaccines-13-00185" ref-type="bibr">54</xref>]. There are several clinical trials assessing the efficacy of DC vaccines (<xref rid="vaccines-13-00185-t003" ref-type="table">Table 3</xref>). A phase I clinical trial (NCT00601094) is aiming to assess the safety, toxicity, and maximum tolerated dose of autologous dendritic cell-adenovirus CCL21, known as AdCCL21-DC, in patients with stage III/IV and recurrent NSCLC [<xref rid="B55-vaccines-13-00185" ref-type="bibr">55</xref>]. Results have not yet been reported. Another phase I clinical trial (NCT01574222) found that the vaccine was safe, with no evidence of free adenovirus in the peripheral blood following vaccination, and no significant changes in anti-adenoviral antibody levels were detected. A systemic immune response was found in 6 out of 16 patients and was directed against tumor-associated antigens (TAAs) as demonstrated through ELISPOT assays. Additionally, there was an average increase of 3.4 times in CD8 T-cell infiltration per mm<sup>2</sup>, with 25% of the patients (4 out of 16) showing a clinical response of SD by day 56 [<xref rid="B56-vaccines-13-00185" ref-type="bibr">56</xref>]. An ongoing clinical trial (NCT03546361) is investigating the efficacy of pembrolizumab in combination with AdCCL21-DC in stage IV NSCLC patients who are either EGFR/ALK wild-type after progression on a PD-L1 inhibitor or EGFR/ALK mutant after progression on TKI therapy. Preliminary studies indicate the infiltration of autologous DCs and T cells into the tumor microenvironment (TME), generating systemic tumor-specific immune responses against multiple tumor antigens [<xref rid="B57-vaccines-13-00185" ref-type="bibr">57</xref>]. Disadvantages of these vaccines are related to their costly and complex production, therefore jeopardizing their wide range utilization. Another limitation is represented by the need for intratumoral administration (i.e., via bronchoscopy) that can limit their application to hospital settings rather than community settings. Side effect profile appears tolerable, as reported in <xref rid="vaccines-13-00185-t003" ref-type="table">Table 3</xref>. The limited efficacy observed in DC vaccines can be attributed to suboptimal protocols that fail to generate an optimal T-cell response. One factor contributing to this limitation is the use of granulocyte-macrophage colony-stimulating factor (GM-CSF) for maturing peripheral blood mononuclear cells, which results in the production of monocyte-derived DCs that have a limited ability to migrate to lymph nodes [<xref rid="B37-vaccines-13-00185" ref-type="bibr">37</xref>,<xref rid="B38-vaccines-13-00185" ref-type="bibr">38</xref>]. The migration of DCs to lymph nodes is crucial for T-cell antigen interaction, and the use of monocyte-derived DC vaccines hampers this essential step [<xref rid="B39-vaccines-13-00185" ref-type="bibr">39</xref>,<xref rid="B40-vaccines-13-00185" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-13-00185" ref-type="bibr">41</xref>].</p><p>Furthermore, it has been highlighted by Roy et al. (2020) [<xref rid="B58-vaccines-13-00185" ref-type="bibr">58</xref>] that the production of DC vaccines can be costly and complex, further posing challenges to their widespread adoption [<xref rid="B58-vaccines-13-00185" ref-type="bibr">58</xref>]. These factors have contributed to the need for refinement in the manufacturing and administration of DC vaccines to enhance their effectiveness.</p></sec><sec id="sec2dot5-vaccines-13-00185"><title>2.5. Allogenic Vaccines</title><p>An allogeneic vaccine is a type of cancer vaccine made from tumor cells that are harvested from donors rather than the patient themselves [<xref rid="B59-vaccines-13-00185" ref-type="bibr">59</xref>] (<xref rid="vaccines-13-00185-f005" ref-type="fig">Figure 5</xref>). These vaccines work by stimulating immune responses, specifically through T cells that recognize certain tumor antigens [<xref rid="B60-vaccines-13-00185" ref-type="bibr">60</xref>]. To ensure safety, the tumor cells are usually irradiated or destroyed before being reinjected into patients, so this process helps to minimize the risk of tumor cell implants or metastasis [<xref rid="B61-vaccines-13-00185" ref-type="bibr">61</xref>]. Numerous clinical trials are currently investigating various allogenic vaccines for oncological applications (<xref rid="vaccines-13-00185-t004" ref-type="table">Table 4</xref>). A phase III clinical trial (NCT00676507), the STOP trial, compared the effectiveness of belagenpumatucel-L with a placebo in patients diagnosed with stage III/IV NSCLC. Unfortunately, this trial did not meet its primary objective, as there was no statistically significant difference in median OS between the two groups. The vaccinated group had a median OS of 20.3 months, while the placebo group had a median OS of 17.8 months (HR 0.94, <italic toggle="yes">p</italic> = 0.594). Additionally, the trial did not meet its secondary endpoint for PFS, with the vaccinated group experiencing a median PFS of 4.3 months versus 4.0 months for the placebo group (HR 0.99, <italic toggle="yes">p</italic> = 0.947) [<xref rid="B62-vaccines-13-00185" ref-type="bibr">62</xref>]. A phase II clinical trial (NCT00601796) evaluated GM.CD40L in combination with cyclophosphamide and tretinoin in patients with stage IIIB/IV lung adenocarcinoma; however, it failed to meet its primary endpoint of inducing radiologic tumor regression even in patients with an immune response to vaccination [<xref rid="B63-vaccines-13-00185" ref-type="bibr">63</xref>]. Another phase Ib/II2 clinical trial (NCT02460367) assessed tergenpumatucel-L in previously treated NSCLC patients but was terminated prematurely due to insufficient enrollment [<xref rid="B64-vaccines-13-00185" ref-type="bibr">64</xref>]. Additionally, a phase II clinical trial (NCT01774578) is currently underway to evaluate tergenpumatucel-L in comparison to docetaxel for patients with advanced NSCLC, although the findings have yet to be disclosed [<xref rid="B65-vaccines-13-00185" ref-type="bibr">65</xref>]. The DURGA trial (NCT02439450), a phase Ib/2 study, examined the safety profile of viagenpumatucel-L in combination with nivolumab. Preliminary results suggest that this combination is safe for patient use [<xref rid="B66-vaccines-13-00185" ref-type="bibr">66</xref>].</p><p>The main advantage found in allogenic vaccine consists in the enhanced immune response that mimics graft versus tumor responses observed in patients who receive mismatched minor histocompatibility antigen bone marrow transplants [<xref rid="B67-vaccines-13-00185" ref-type="bibr">67</xref>]. Other advantages are availability, low production cost, and the lack of invasive procedures as they are administered intradermally with tolerable side effects as reported in <xref rid="vaccines-13-00185-t004" ref-type="table">Table 4</xref>. Disadvantages are represented by the fact that irradiated cells may retain the ability to secrete immunosuppressive factors like the original tumor cells [<xref rid="B68-vaccines-13-00185" ref-type="bibr">68</xref>,<xref rid="B69-vaccines-13-00185" ref-type="bibr">69</xref>].</p></sec><sec id="sec2dot6-vaccines-13-00185"><title>2.6. Messenger RNA (mRNA) Vaccines</title><p>mRNA vaccines represent a significant advancement in biotechnology by delivering genetic information that encodes target antigens in the form of mRNA, which is subsequently translated within the cytoplasm of cells [<xref rid="B70-vaccines-13-00185" ref-type="bibr">70</xref>]. Upon entry into the cells, ribosomes translate the mRNA into proteins, which are then presented on the surface of the host cells [<xref rid="B71-vaccines-13-00185" ref-type="bibr">71</xref>] (<xref rid="vaccines-13-00185-f006" ref-type="fig">Figure 6</xref>). These vaccines gained widespread recognition during the COVID-19 pandemic, as they became the first approved vaccines with a preventive efficacy of 95% [<xref rid="B72-vaccines-13-00185" ref-type="bibr">72</xref>]. The expedited development of mRNA vaccines for COVID-19 has highlighted the remarkable potential of mRNA technology, which is currently being explored for use in cancer treatments, leading to notable clinical advances in ongoing trials [<xref rid="B73-vaccines-13-00185" ref-type="bibr">73</xref>] (<xref rid="vaccines-13-00185-t005" ref-type="table">Table 5</xref>). These vaccines also offer significant advantages by addressing key limitations of traditional vaccines. They provide information on tumor-specific antigens, allowing for precise identification and targeting cancer cells while also fostering robust and lasting immune responses against tumors [<xref rid="B74-vaccines-13-00185" ref-type="bibr">74</xref>]. The phase I clinical trial (NCT05142189), known as LuCa-MERIT-1, currently recruiting, is testing the mRNA vaccine BNT116 in patients with advanced NSCLC who have a PD-L1 expression of &#x02265;50% after receiving anti-PD-L1 therapy. The vaccine is composed of six mRNAs (MAGE A3, CLDN6, KK-LC-1, PRAME, MAGE A4, MAGE C1), each of which encodes tumor-associated antigens (TAAs) commonly found in NSCLC. Preliminary results indicated that 35% of patients had PR and 50% had SD, according to the RECIST v1.1 criteria [<xref rid="B75-vaccines-13-00185" ref-type="bibr">75</xref>]. In addition, there are two phase III clinical trials, NCT06623422 and NCT06077760, that are actively recruiting patients with resected stage II, IIIA, and IIIB NSCLC. These trials aim to evaluate the mRNA vaccine V940 in combination with pembrolizumab in the adjuvant space, compared to pembrolizumab plus placebo [<xref rid="B76-vaccines-13-00185" ref-type="bibr">76</xref>,<xref rid="B77-vaccines-13-00185" ref-type="bibr">77</xref>]. Results from these trials have not yet been reported. Advantages of mRNA vaccines are high potency, safe administration, rapid development potential, and cost-effective manufacturing.</p></sec><sec id="sec2dot7-vaccines-13-00185"><title>2.7. Neoantigens Vaccines</title><p>Neoantigens, short peptide sequences expressed only by tumor tissues, are unique to each patient and tumor. This option provides a solution to challenges posed by resistance to current prevailing standard of care treatments such as ICIs, commonly utilized in the treatment of NSCLC. While the vaccines discussed thus far in this article are personalized in that they target TAAs, they have been conducted on a relatively small number of patients, and larger scale prospective studies are required. There are several studies underway to facilitate development of neoantigen vaccines. One such example is the phase I/II clinical trial NCT03953235, the purpose of which is to evaluate the safety, dose, immunogenicity and early clinical activity of GRT-C903 and GRT-R904, a personalized neoantigen cancer vaccine, in combination with nivolumab and ipilimumab, in patients with metastatic non-small cell lung cancer, microsatellite stable colorectal cancer, gastroesophageal adenocarcinoma, and metastatic urothelial cancer. This study was completed in 2024, and its results are still pending [<xref rid="B78-vaccines-13-00185" ref-type="bibr">78</xref>]. Another example is NCT03908671, testing a personalized RNA vaccine encoding neoantigens in the treatment of NSCLC [<xref rid="B79-vaccines-13-00185" ref-type="bibr">79</xref>].</p></sec></sec><sec id="sec3-vaccines-13-00185"><title>3. SCLC Therapeutic Vaccines</title><p>SCLC comprises 15% of all lung cancer diagnoses and is recognized as one of the most aggressive forms of lung cancer [<xref rid="B80-vaccines-13-00185" ref-type="bibr">80</xref>]. It accounts for about 15% of all lung cancers worldwide and is notable for its propensity for rapid proliferation and early metastasis. Despite the initial positive response to treatments like chemotherapy and radiation, SCLC poses a dire threat, as the majority of patients experience recurrence often accompanied by metastasis to distant sites, leading to a staggering survival rate of under 5% over five years, while those not receiving any active treatment usually survive just 2 to 4 months [<xref rid="B81-vaccines-13-00185" ref-type="bibr">81</xref>]. The treatment landscape for SCLC has seen limited advancements, with its first-line therapy remaining unchanged for over three decades; however, recent developments offer a renewed sense of optimism [<xref rid="B82-vaccines-13-00185" ref-type="bibr">82</xref>]. Recently, there has been an increase in understanding of the molecular alterations causing SCLC, leading to the integration of immunotherapy in standard treatment regimens. The integration of ICIs such as atezolizumab and durvalumab targeting PD-L1 into first-line treatment regimens has been demonstrated to improve both OS and PFS [<xref rid="B83-vaccines-13-00185" ref-type="bibr">83</xref>]. Recent developments have led to the approval of the bispecific T-cell engager (BiTE) tarlatamab after failure of first-line treatment [<xref rid="B84-vaccines-13-00185" ref-type="bibr">84</xref>]. PARP inhibitors and antibody drug conjugates targeting DLL3, a NOTCH ligand, represent emerging therapies showing promising results in ongoing trials [<xref rid="B85-vaccines-13-00185" ref-type="bibr">85</xref>]. Notably, the exploration of vaccine therapies presents a biologically driven approach aimed at addressing residual cancer cells, underscoring potential progress in the management of this challenging disease [<xref rid="B86-vaccines-13-00185" ref-type="bibr">86</xref>]. <xref rid="vaccines-13-00185-t006" ref-type="table">Table 6</xref> lists completed and current clinical trials of cancer vaccines in SCLC.</p><sec id="sec3dot1-vaccines-13-00185"><title>3.1. Combined Vaccine with the Bacillus Calmette-Gu&#x000e9;rin</title><p>Bacillus Calmette-Guerin (BCG) is mainly used to treat non-muscle-invasive bladder cancer [<xref rid="B87-vaccines-13-00185" ref-type="bibr">87</xref>]. It works by activating natural killer (NK) cells and CD8+ T cells, which helps boost the immune response against cancer [<xref rid="B88-vaccines-13-00185" ref-type="bibr">88</xref>]. This live vaccine has also been studied for use in other types of cancer. For instance, the Silva trial, a completed phase III clinical study (NCT00037713, NCT00003279, NCT00006352), assessed the effectiveness of BEC-2, an anti-idiotypic antibody targeting GD3, combined with BCG in 515 patients with limited disease SCLC [<xref rid="B89-vaccines-13-00185" ref-type="bibr">89</xref>,<xref rid="B90-vaccines-13-00185" ref-type="bibr">90</xref>,<xref rid="B91-vaccines-13-00185" ref-type="bibr">91</xref>]. The study was performed between March 1998 and October 2002 [<xref rid="B92-vaccines-13-00185" ref-type="bibr">92</xref>,<xref rid="B93-vaccines-13-00185" ref-type="bibr">93</xref>]. However, the results showed no significant improvements in survival rates (16.4 and 14.3 months <italic toggle="yes">p</italic> = 0.28), PFS, or quality of life for the vaccination group [<xref rid="B94-vaccines-13-00185" ref-type="bibr">94</xref>]. One advantage of this vaccine is that it is administered intradermally and has tolerable side effects.</p></sec><sec id="sec3dot2-vaccines-13-00185"><title>3.2. Tumor Glycans Vaccines</title><p>Tumor-associated carbohydrate antigens (TACAs), such as O-glycans, gangliosides, globo-series glycans, Lewis antigens, and polysialic acid, are produced through abnormal glycosylation processes in tumor cells and play a crucial role in metastasis and signal transduction [<xref rid="B95-vaccines-13-00185" ref-type="bibr">95</xref>]. Vaccines that incorporate TACA antigens are absorbed by antigen-presenting cells via endocytosis. Once inside the cells, these antigens are processed and presented through the MHC class I and II pathways, which stimulates an immune response against cancer [<xref rid="B96-vaccines-13-00185" ref-type="bibr">96</xref>]. When combined with other anti-tumor strategies, these vaccines represent a promising approach to cancer treatment [<xref rid="B97-vaccines-13-00185" ref-type="bibr">97</xref>]. The pentavalent KLH conjugate vaccine contains five antigens: GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid, all linked to an immunostimulant called keyhole limpet hemocyanin (KLH) [<xref rid="B98-vaccines-13-00185" ref-type="bibr">98</xref>]. The completed phase 1 clinical trial, NCT01349647, tested the pentavalent KLH conjugate vaccine in patients with SCLC, but results have not been posted yet [<xref rid="B99-vaccines-13-00185" ref-type="bibr">99</xref>].</p></sec><sec id="sec3dot3-vaccines-13-00185"><title>3.3. Peptide/Protein with Dendritic Cell (DC) Vaccine</title><p>Numerous cancer-specific antigen vaccines have been developed for the treatment of SCLC, either alone or in combination with DCs. Creating a DC vaccine involves several steps. First, DCs are separated from the patient&#x02019;s blood. They are then activated and loaded with antigens outside the body (ex vivo) before being reinfused into the patient to stimulate an immune response against cancer [<xref rid="B100-vaccines-13-00185" ref-type="bibr">100</xref>]. One of the antigens explored in tumor vaccine development is P53, a crucial regulator of various cellular processes, including cell growth, immune responses, and multiple signaling pathways [<xref rid="B101-vaccines-13-00185" ref-type="bibr">101</xref>]. Its inactivation is almost universally observed in human cancer cells, significantly impacting advancements in cancer therapeutics [<xref rid="B102-vaccines-13-00185" ref-type="bibr">102</xref>]. P53-based peptide vaccines are designed to trigger an anti-tumor immune response by targeting the p53 protein [<xref rid="B103-vaccines-13-00185" ref-type="bibr">103</xref>]. Another antigen explored in this field is the RAS protein, which plays an important role in signal transduction within cellular membranes, but dysregulation of this protein can lead to cancer [<xref rid="B104-vaccines-13-00185" ref-type="bibr">104</xref>]. RAS peptide cancer vaccines aim to enhance the activation of a RAS peptide-specific anti-tumoral T-cell cytotoxic immune response, which may help inhibit tumor cell growth and promote tumor cell death [<xref rid="B105-vaccines-13-00185" ref-type="bibr">105</xref>]. A completed phase II clinical trial, referred to as NCT00019084, evaluated the efficacy of P53 or RAS peptide vaccines, either independently or in combination with the patient&#x02019;s own peptide-activated lymphocytes and subcutaneous administration of interleukin-2, a cytokine that enhances the immune response in cancer therapy [<xref rid="B106-vaccines-13-00185" ref-type="bibr">106</xref>,<xref rid="B107-vaccines-13-00185" ref-type="bibr">107</xref>]. One advantage of these vaccines is that they are administered intravenously. However, the results of this trial have yet to be disclosed. The Ad.p53-DC vaccine is a type of cancer immunotherapy that involves using a patient&#x02019;s DCs that have been modified with a recombinant adenovirus carrying the p53 peptide, which may enhance immune response [<xref rid="B108-vaccines-13-00185" ref-type="bibr">108</xref>]. Numerous clinical trials are currently underway to assess the Ad.p53-DC vaccine. The phase II clinical trial NCT03406715 is investigating the Ad/p53-DC vaccine in conjunction with immunotherapeutic agents nivolumab and ipilimumab [<xref rid="B109-vaccines-13-00185" ref-type="bibr">109</xref>]. Two clinical trials, NCT00049218 (phase I/II) and NCT00617409 (phase II), are focused on evaluating the effectiveness of chemotherapy followed by the administration of the Ad.p53-DC vaccine in patients with extensive-stage SCLC [<xref rid="B110-vaccines-13-00185" ref-type="bibr">110</xref>,<xref rid="B111-vaccines-13-00185" ref-type="bibr">111</xref>]. The phase II clinical trial also explores the combination of chemotherapy with or without all-trans retinoic acid, a compound that the human body produces from vitamin A and that aids in cell growth and development [<xref rid="B112-vaccines-13-00185" ref-type="bibr">112</xref>]. One advantage of this vaccine is that it is administered intradermally. The phase I/II clinical trial NCT00049218, also known as INGN-225, assessed the safety and tolerability of the Ad.p53-DC vaccine in 54 patients with SCLC. Clinical responses correlated with positive immune responses in 11 out of 14 (79%). In contrast, only 5 out of 15 (33%) patients with a negative immune response met the RECIST criteria for clinical response (<italic toggle="yes">p</italic> = 0.014) [<xref rid="B113-vaccines-13-00185" ref-type="bibr">113</xref>]. In general, advantages of peptide vaccines are ease of synthesis, low production costs, low carcinogenic potential, high chemical stability, and tolerable side effects (<xref rid="vaccines-13-00185-t006" ref-type="table">Table 6</xref>). The disadvantages are low immunogenicity, requiring combination therapies.</p></sec></sec><sec sec-type="conclusions" id="sec4-vaccines-13-00185"><title>4. Conclusions</title><p>This review provides an analysis of various strategies for vaccine development, summarizing results of both completed and ongoing clinical trials. These efforts are crucial in enhancing treatment options for both NSCLC and SCLC patients. Despite the progress made in research and development, many trials have encountered significant challenges in meeting their primary endpoints, reflecting the inherent difficulties in effectively targeting these aggressive forms of cancer. Given that lung cancer remains the leading cause of cancer-related mortality among both men and women, with a concerning five-year survival rate of only 28.4% following diagnosis, there is a pressing need for innovative therapeutic strategies to enhance vaccine outcomes [<xref rid="B114-vaccines-13-00185" ref-type="bibr">114</xref>].</p><p>Currently, there are several promising vaccine clinical trials in progress aimed at improving the landscape of lung cancer treatment. However, it is noteworthy that, to date, only four therapeutic cancer vaccines have received FDA approval. Disturbingly, none of these vaccines are specifically designated for lung cancer treatment. Among the few approved options, the peptide and protein vaccines stand out, specifically CIMAvax-EGF vaccine in combination with or without nivolumab. The CIMAvax vaccine has been approved in Latin America, where it has demonstrated a median OS of 14.6 months (95% CI 10.6&#x02013;18.8) and a PFS of 8.16 months (95% CI 4.9&#x02013;11.3) for patients with NSCLC as a maintenance therapy [<xref rid="B16-vaccines-13-00185" ref-type="bibr">16</xref>]. The CIMAvax vaccine combined with nivolumab has shown an OS of 11.9 months (90% CI 8.0&#x02013;23.9) in patients with late-stage NSCLC requiring systemic therapy [<xref rid="B18-vaccines-13-00185" ref-type="bibr">18</xref>]. The importance of this endeavor is immense, as progress in vaccine development could significantly enhance survival rates and the quality of life for individuals battling lung cancer.</p></sec><sec id="sec5-vaccines-13-00185"><title>5. Expert Opinion</title><p>A significant number of clinical trials conducted thus far in lung cancer have primarily engaged patients who have not responded to conventional first- and second-line therapies, as well as ICIs and tyrosine kinase inhibitors (TKIs). It is important to recognize that many patients are diagnosed at advanced stages of their diseases, including late-stage, unresectable, incurable, or metastatic conditions. This has a considerable impact on their prognosis and makes treatment options more complex. This group often exhibits signs of immunosuppression as a consequence of prior chemotherapy treatments and bulky disease burden correlated with an immunosuppressed TME, which can substantially impair their response to vaccine therapies. Therefore, a more promising strategy might involve the enrollment of patients at earlier stages of the disease or during the phase of early detection. This approach enables more timely and effective treatment through the utilization of immunotherapy options, such as combined ICIs and tumor vaccines, in conjunction with established chemotherapy regimens.</p><p>Another significant challenge that vaccine implementation faces is the variability of molecular gene alterations associated with tumorigenesis. Notably, the clinical trial NCT02955290 has demonstrated that patients with EGFR, ALK, or KRAS wild-type profiles achieve significantly better outcomes when treated with CIMAvax-EGF in combination with nivolumab, resulting in a median OS of 31.7 months (90% CI 5.9, NR) and a 3-year OS rate of 50% (90% CI 24, 71), whereas patients with KRAS mutations have a median OS of only 10.1 months (90% CI 6.5, 12.1) and a 3-year OS rate of 0% (90% CI 1, 41) [<xref rid="B18-vaccines-13-00185" ref-type="bibr">18</xref>]. This difference in outcomes may be due to the fact that KRAS-mutated lung cancers often develop multiple resistance mechanisms, which can alter the effectiveness of immunotherapy treatments, including tumor vaccines. The same study suggests that patients with PD-L1 expression levels of &#x02265;1% may have significantly greater benefit from a combination of ICIs and tumor vaccination compared to their counterparts with PD-L1 &#x02264;1% [<xref rid="B18-vaccines-13-00185" ref-type="bibr">18</xref>]. Therefore, it might be advisable to focus the development of optimal tumor vaccines on patients exhibiting PD-L1 expression levels of 1% or higher without driver gene alterations.</p><p>Additionally, tumor vaccines are instrumental in enhancing T-cell infiltration in tumors and antigen presentation. Therefore, appropriate sequencing of delivery of vaccines in respect to combined treatments such as ICIs may be a key factor in eliciting the strongest immune response as demonstrated in studies by Sousa et al. [<xref rid="B115-vaccines-13-00185" ref-type="bibr">115</xref>].</p><p>Investigating the immune response variability in NSCLC is essential for identifying significant biomarkers. A notable example is the CIMAvax-EGF vaccine, which has demonstrated improved outcomes for patients with elevated serum EGF levels [<xref rid="B15-vaccines-13-00185" ref-type="bibr">15</xref>]. Therefore, it is imperative to identify more precise markers that can predict which patients are likely to benefit from this therapy, particularly after the vaccine has established its efficacy. In fact, monitoring immune response at defined time points after vaccination is essential to decide if patients are benefiting from this approach preventing rapid progression of disease.</p><p>Novel approaches in developing vaccine delivery systems to overcome tumor heterogeneity involve the incorporation of artificial intelligence (AI), nanoparticle technology, and the use of embryonic stem cells (ESCs). AI can aid in extracting large datasets and training models to predict patient-specific cancer antigens as well as assessment of vaccine immunogenicity. This information can help guide the design and formulation of vaccines, with several models demonstrating promise in supporting traditional methods and holds potential for creating more personalized and targeted therapies [<xref rid="B116-vaccines-13-00185" ref-type="bibr">116</xref>].</p><p>The use of nanovaccines that employ nanoparticles, which range from 50 to 200 nm in diameter and serve as carriers and/or adjuvants, has been demonstrated to improve delivery effectiveness in vitro and in vivo [<xref rid="B117-vaccines-13-00185" ref-type="bibr">117</xref>]. These nanovaccines can boost the activation of CD8+ T cells by at least 55 times in comparison to soluble antigens, which can overcome immunosuppressive TME signals. They can also specifically target tumor sites and aid in delivery to the lymphatic system. Additionally, they can be tailored according to the unique characteristics of a patient&#x02019;s tumor, providing potential for targeting heterogeneity in tumor metastasis [<xref rid="B117-vaccines-13-00185" ref-type="bibr">117</xref>]. Recent studies showed that irradiated, induced pluripotent stem cells (iPSCs) function as a prophylactic vaccine against transplanted tumors by eliciting anti-tumor immune responses [<xref rid="B118-vaccines-13-00185" ref-type="bibr">118</xref>,<xref rid="B119-vaccines-13-00185" ref-type="bibr">119</xref>]. Shared expression of antigens between ESCs and lung cancer cells might induce immunity against pulmonary malignancy [<xref rid="B120-vaccines-13-00185" ref-type="bibr">120</xref>].</p><p>Undifferentiated ESC vaccines appear to be more effective in preventing lung tumor development in a Lewis lung mouse model as they overexpress certain antigens, including carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), and CTA that can enhance immunogenicity [<xref rid="B121-vaccines-13-00185" ref-type="bibr">121</xref>].</p><p>In conclusion, cancer vaccines represent useful additions to standard treatments such ICIs, chemotherapy, and radiation therapy to improve outcomes especially in early stage lung cancer in light of availability of innovative approaches such as AI, nanovaccines, and ESCs.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>J.S.F.B., S.G., F.R. and E.M. have contributed to methodology, writing&#x02014;original draft, review, resources, editing, and visualization. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>No new data were created or analyzed in this study. Data sharing is not applicable to this article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript.<array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">AI</td><td align="left" valign="middle" rowspan="1" colspan="1">Artificial intelligence</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ALK</td><td align="left" valign="middle" rowspan="1" colspan="1">Anaplastic lymphoma kinase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">APC</td><td align="left" valign="middle" rowspan="1" colspan="1">Antigen-presenting cell</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BCG</td><td align="left" valign="middle" rowspan="1" colspan="1">Bacillus Calmette-Guerin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BiTE</td><td align="left" valign="middle" rowspan="1" colspan="1">Bispecific T-cell engager</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CBI</td><td align="left" valign="middle" rowspan="1" colspan="1">Checkpoint blockade immunotherapy</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CEA</td><td align="left" valign="middle" rowspan="1" colspan="1">Carcinoembryonic antigen</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CTA</td><td align="left" valign="middle" rowspan="1" colspan="1">Cancer/testis antigen</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CTL</td><td align="left" valign="middle" rowspan="1" colspan="1">Cytotoxic T-lymphocyte</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DC</td><td align="left" valign="middle" rowspan="1" colspan="1">Dendritic cell</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EGF</td><td align="left" valign="middle" rowspan="1" colspan="1">Epidermal growth factor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EGFR</td><td align="left" valign="middle" rowspan="1" colspan="1">Epidermal growth factor receptor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ESCs</td><td align="left" valign="middle" rowspan="1" colspan="1">Embryonic stem cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EML-4</td><td align="left" valign="middle" rowspan="1" colspan="1">Echinoderm microtubule-associated protein-like 4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FDA</td><td align="left" valign="middle" rowspan="1" colspan="1">Food and Drug Administration</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GM-CSF</td><td align="left" valign="middle" rowspan="1" colspan="1">Granulocyte-macrophage colony-stimulating factor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ICIs</td><td align="left" valign="middle" rowspan="1" colspan="1">Immune checkpoint inhibitors</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IL-12</td><td align="left" valign="middle" rowspan="1" colspan="1">Interleukin 12</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IL-23</td><td align="left" valign="middle" rowspan="1" colspan="1">Interleukin 23</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">iPSC</td><td align="left" valign="middle" rowspan="1" colspan="1">Irradiated pluripotent stem cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">KLH</td><td align="left" valign="middle" rowspan="1" colspan="1">Keyhole limpet hemocyanin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MAGE-A3</td><td align="left" valign="middle" rowspan="1" colspan="1">Melanoma antigen family A, 3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MHC I</td><td align="left" valign="middle" rowspan="1" colspan="1">Major histocompatibility complex I</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MHC II</td><td align="left" valign="middle" rowspan="1" colspan="1">Major histocompatibility complex</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MOS</td><td align="left" valign="middle" rowspan="1" colspan="1">Median overall survival</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MUC 1</td><td align="left" valign="middle" rowspan="1" colspan="1">Mucin 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NK</td><td align="left" valign="middle" rowspan="1" colspan="1">Natural killer</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">Non-small cell lung cancer</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NY-ESO-1</td><td align="left" valign="middle" rowspan="1" colspan="1">New York esophageal squamous cell carcinoma</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OS</td><td align="left" valign="middle" rowspan="1" colspan="1">Overall survival</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PFS</td><td align="left" valign="middle" rowspan="1" colspan="1">Progression-free survival</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PR</td><td align="left" valign="middle" rowspan="1" colspan="1">Partial response</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PSA</td><td align="left" valign="middle" rowspan="1" colspan="1">Prostate-specific antigen</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RECIST</td><td align="left" valign="middle" rowspan="1" colspan="1">Response Evaluation Criteria in Solid Tumors</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">Small cell lung cancer</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SD</td><td align="left" valign="middle" rowspan="1" colspan="1">Stable disease</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TAAs</td><td align="left" valign="middle" rowspan="1" colspan="1">Tumor-associated antigens</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TACA</td><td align="left" valign="middle" rowspan="1" colspan="1">Tumor-associated carbohydrate antigens</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TCR</td><td align="left" valign="middle" rowspan="1" colspan="1">T-cell receptor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TKIs</td><td align="left" valign="middle" rowspan="1" colspan="1">Tyrosine kinase inhibitors</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TME</td><td align="left" valign="middle" rowspan="1" colspan="1">Tumor microenvironment</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TNF-&#x003b1;</td><td align="left" valign="middle" rowspan="1" colspan="1">Tumor necrosis factor alpha</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-vaccines-13-00185"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schabath</surname><given-names>M.B.</given-names></name>
<name><surname>Cote</surname><given-names>M.L.</given-names></name>
</person-group><article-title>Cancer Progress and Priorities: Lung Cancer</article-title><source>Cancer Epidemiol. Biomark. Prev.</source><year>2019</year><volume>28</volume><fpage>1563</fpage><lpage>1579</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-19-0221</pub-id></element-citation></ref><ref id="B2-vaccines-13-00185"><label>2.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>Kelly</surname><given-names>R.J.</given-names></name>
<name><surname>Giaccone</surname><given-names>G.</given-names></name>
</person-group><article-title>Lung Cancer Vaccines</article-title><year>2011</year><comment>Available online: <ext-link xlink:href="www.journalppo.com" ext-link-type="uri">www.journalppo.com</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-01">(accessed on 1 December 2024)</date-in-citation></element-citation></ref><ref id="B3-vaccines-13-00185"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Cheng</surname><given-names>S.</given-names></name>
<name><surname>Cai</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>P.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>F.</given-names></name>
<name><surname>Chen</surname><given-names>K.</given-names></name>
<name><surname>Qiu</surname><given-names>M.</given-names></name>
</person-group><article-title>The Current Therapeutic Cancer Vaccines Landscape in Non-Small Cell Lung Cancer</article-title><source>Int. J. Cancer</source><year>2024</year><volume>155</volume><fpage>1909</fpage><lpage>1927</lpage><pub-id pub-id-type="doi">10.1002/ijc.35088</pub-id><pub-id pub-id-type="pmid">39109825</pub-id>
</element-citation></ref><ref id="B4-vaccines-13-00185"><label>4.</label><element-citation publication-type="webpage"><article-title>Cancer Vaccines: The Types, How They Work, and Which Cancers They Treat|Memorial Sloan Kettering Cancer Center</article-title><comment>Available online: <ext-link xlink:href="https://www.mskcc.org/cancer-care/diagnosis-treatment/cancer-treatments/immunotherapy/cancer-vaccines" ext-link-type="uri">https://www.mskcc.org/cancer-care/diagnosis-treatment/cancer-treatments/immunotherapy/cancer-vaccines</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-29">(accessed on 29 December 2024)</date-in-citation></element-citation></ref><ref id="B5-vaccines-13-00185"><label>5.</label><element-citation publication-type="gov"><article-title>Home|ClinicalTrials.gov</article-title><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/" ext-link-type="uri">https://clinicaltrials.gov/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-24">(accessed on 24 December 2024)</date-in-citation></element-citation></ref><ref id="B6-vaccines-13-00185"><label>6.</label><element-citation publication-type="webpage"><article-title>Histologic Subtype in NSCLC: Does It Matter?</article-title><comment>Available online: <ext-link xlink:href="https://www.cancernetwork.com/view/histologic-subtype-nsclc-does-it-matter" ext-link-type="uri">https://www.cancernetwork.com/view/histologic-subtype-nsclc-does-it-matter</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-24">(accessed on 24 December 2024)</date-in-citation></element-citation></ref><ref id="B7-vaccines-13-00185"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Relli</surname><given-names>V.</given-names></name>
<name><surname>Trerotola</surname><given-names>M.</given-names></name>
<name><surname>Guerra</surname><given-names>E.</given-names></name>
<name><surname>Alberti</surname><given-names>S.</given-names></name>
</person-group><article-title>Abandoning the Notion of Non-Small Cell Lung Cancer</article-title><source>Trends Mol. Med.</source><year>2019</year><volume>25</volume><fpage>585</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2019.04.012</pub-id><pub-id pub-id-type="pmid">31155338</pub-id>
</element-citation></ref><ref id="B8-vaccines-13-00185"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Z.</given-names></name>
<name><surname>Fillmore</surname><given-names>C.M.</given-names></name>
<name><surname>Hammerman</surname><given-names>P.S.</given-names></name>
<name><surname>Kim</surname><given-names>C.F.</given-names></name>
<name><surname>Wong</surname><given-names>K.K.</given-names></name>
</person-group><article-title>Non-Small-Cell Lung Cancers: A Heterogeneous Set of Diseases</article-title><source>Nat. Rev. Cancer</source><year>2014</year><volume>14</volume><fpage>535</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1038/nrc3775</pub-id><pub-id pub-id-type="pmid">25056707</pub-id>
</element-citation></ref><ref id="B9-vaccines-13-00185"><label>9.</label><element-citation publication-type="gov"><article-title>Non-Small Cell Lung Cancer Treatment (PDQ&#x000ae;)&#x02014;NCI</article-title><comment>Available online: <ext-link xlink:href="https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq" ext-link-type="uri">https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-29">(accessed on 29 January 2025)</date-in-citation></element-citation></ref><ref id="B10-vaccines-13-00185"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meyer</surname><given-names>M.L.</given-names></name>
<name><surname>Fitzgerald</surname><given-names>B.G.</given-names></name>
<name><surname>Paz-Ares</surname><given-names>L.</given-names></name>
<name><surname>Cappuzzo</surname><given-names>F.</given-names></name>
<name><surname>J&#x000e4;nne</surname><given-names>P.A.</given-names></name>
<name><surname>Peters</surname><given-names>S.</given-names></name>
<name><surname>Hirsch</surname><given-names>F.R.</given-names></name>
</person-group><article-title>New Promises and Challenges in the Treatment of Advanced Non-Small-Cell Lung Cancer</article-title><source>Lancet</source><year>2024</year><volume>404</volume><fpage>803</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(24)01029-8</pub-id><pub-id pub-id-type="pmid">39121882</pub-id>
</element-citation></ref><ref id="B11-vaccines-13-00185"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nakahara</surname><given-names>Y.</given-names></name>
<name><surname>Kouro</surname><given-names>T.</given-names></name>
<name><surname>Igarashi</surname><given-names>Y.</given-names></name>
<name><surname>Kawahara</surname><given-names>M.</given-names></name>
<name><surname>Sasada</surname><given-names>T.</given-names></name>
</person-group><article-title>Prospects for a Personalized Peptide Vaccine against Lung Cancer</article-title><source>Expert Rev. Vaccines</source><year>2019</year><volume>18</volume><fpage>703</fpage><lpage>709</lpage><pub-id pub-id-type="doi">10.1080/14760584.2019.1635461</pub-id><pub-id pub-id-type="pmid">31225971</pub-id>
</element-citation></ref><ref id="B12-vaccines-13-00185"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Awad</surname><given-names>M.M.</given-names></name>
<name><surname>Govindan</surname><given-names>R.</given-names></name>
<name><surname>Balogh</surname><given-names>K.N.</given-names></name>
<name><surname>Spigel</surname><given-names>D.R.</given-names></name>
<name><surname>Garon</surname><given-names>E.B.</given-names></name>
<name><surname>Bushway</surname><given-names>M.E.</given-names></name>
<name><surname>Poran</surname><given-names>A.</given-names></name>
<name><surname>Sheen</surname><given-names>J.H.</given-names></name>
<name><surname>Kohler</surname><given-names>V.</given-names></name>
<name><surname>Esaulova</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Personalized Neoantigen Vaccine NEO-PV-01 with Chemotherapy and Anti-PD-1 as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer</article-title><source>Cancer Cell</source><year>2022</year><volume>40</volume><fpage>1010</fpage><lpage>1026.e11</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2022.08.003</pub-id><pub-id pub-id-type="pmid">36027916</pub-id>
</element-citation></ref><ref id="B13-vaccines-13-00185"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tomas</surname><given-names>A.</given-names></name>
<name><surname>Futter</surname><given-names>C.E.</given-names></name>
<name><surname>Eden</surname><given-names>E.R.</given-names></name>
</person-group><article-title>EGF Receptor Trafficking: Consequences for Signaling and Cancer</article-title><source>Trends Cell Biol.</source><year>2014</year><volume>24</volume><fpage>26</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2013.11.002</pub-id><pub-id pub-id-type="pmid">24295852</pub-id>
</element-citation></ref><ref id="B14-vaccines-13-00185"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tagliamento</surname><given-names>M.</given-names></name>
<name><surname>Rijavec</surname><given-names>E.</given-names></name>
<name><surname>Barletta</surname><given-names>G.</given-names></name>
<name><surname>Biello</surname><given-names>F.</given-names></name>
<name><surname>Rossi</surname><given-names>G.</given-names></name>
<name><surname>Grossi</surname><given-names>F.</given-names></name>
<name><surname>Genova</surname><given-names>C.</given-names></name>
</person-group><article-title>CIMAvax-EGF, a Therapeutic Non-Small Cell Lung Cancer Vaccine</article-title><source>Expert Opin. Biol. Ther.</source><year>2018</year><volume>18</volume><fpage>829</fpage><lpage>835</lpage><pub-id pub-id-type="doi">10.1080/14712598.2018.1492539</pub-id><pub-id pub-id-type="pmid">29936901</pub-id>
</element-citation></ref><ref id="B15-vaccines-13-00185"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Crombet Ramos</surname><given-names>T.</given-names></name>
<name><surname>Santos Morales</surname><given-names>O.</given-names></name>
<name><surname>Dy</surname><given-names>G.K.</given-names></name>
<name><surname>Le&#x000f3;n Monz&#x000f3;n</surname><given-names>K.</given-names></name>
<name><surname>Lage D&#x000e1;vila</surname><given-names>A.</given-names></name>
</person-group><article-title>The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer</article-title><source>Front. Oncol.</source><year>2021</year><volume>11</volume><elocation-id>639745</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2021.639745</pub-id><pub-id pub-id-type="pmid">34211836</pub-id>
</element-citation></ref><ref id="B16-vaccines-13-00185"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vega</surname><given-names>Y.I.F.</given-names></name>
<name><surname>Gonz&#x000e1;lez</surname><given-names>D.L.P.</given-names></name>
<name><surname>Sarmiento</surname><given-names>S.C.A.</given-names></name>
<name><surname>Tul</surname><given-names>L.E.A.</given-names></name>
<name><surname>Vald&#x000e9;s</surname><given-names>I.B.I.</given-names></name>
<name><surname>MacHado</surname><given-names>J.R.</given-names></name>
<name><surname>Larrinaga</surname><given-names>&#x000c1;.E.</given-names></name>
<name><surname>Rodr&#x000ed;guez</surname><given-names>J.E.F.</given-names></name>
<name><surname>Garc&#x000ed;a</surname><given-names>J.L.</given-names></name>
<name><surname>Otero</surname><given-names>D.C.</given-names></name>
<etal/>
</person-group><article-title>Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario</article-title><source>J. Cancer</source><year>2023</year><volume>14</volume><fpage>874</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.7150/jca.67189</pub-id><pub-id pub-id-type="pmid">37056397</pub-id>
</element-citation></ref><ref id="B17-vaccines-13-00185"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dammeijer</surname><given-names>F.</given-names></name>
<name><surname>Lievense</surname><given-names>L.A.</given-names></name>
<name><surname>Veerman</surname><given-names>G.D.M.</given-names></name>
<name><surname>Hoogsteden</surname><given-names>H.C.</given-names></name>
<name><surname>Hegmans</surname><given-names>J.P.</given-names></name>
<name><surname>Arends</surname><given-names>L.R.</given-names></name>
<name><surname>Aerts</surname><given-names>J.G.</given-names></name>
</person-group><article-title>Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis</article-title><source>J. Clin. Oncol.</source><year>2016</year><volume>34</volume><fpage>3204</fpage><lpage>3212</lpage><pub-id pub-id-type="doi">10.1200/JCO.2015.66.3955</pub-id><pub-id pub-id-type="pmid">27432922</pub-id>
</element-citation></ref><ref id="B18-vaccines-13-00185"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Frascati</surname><given-names>R.</given-names></name>
<name><surname>Early</surname><given-names>A.P.</given-names></name>
<name><surname>Reid</surname><given-names>M.E.</given-names></name>
<name><surname>Lee</surname><given-names>K.</given-names></name>
<name><surname>Muhitch</surname><given-names>J.</given-names></name>
<name><surname>Mesa</surname><given-names>C.</given-names></name>
<name><surname>Luaces</surname><given-names>P.L.</given-names></name>
<name><surname>Santos-Morales</surname><given-names>O.</given-names></name>
<name><surname>Dozier</surname><given-names>A.</given-names></name>
<name><surname>Puzanov</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>Final Results from a Phase II Trial of CIMAvax-EGF and Nivolumab as Second-Line (2L) Therapy after Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC)</article-title><source>J. Clin. Oncol.</source><year>2023</year><volume>41</volume><issue>(Suppl. 16)</issue><fpage>9135</fpage><pub-id pub-id-type="doi">10.1200/JCO.2023.41.16_suppl.9135</pub-id></element-citation></ref><ref id="B19-vaccines-13-00185"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>K.</given-names></name>
<name><surname>Krone</surname><given-names>M.W.</given-names></name>
<name><surname>Butrin</surname><given-names>A.</given-names></name>
<name><surname>Bond</surname><given-names>M.J.</given-names></name>
<name><surname>Linhares</surname><given-names>B.M.</given-names></name>
<name><surname>Crews</surname><given-names>C.M.</given-names></name>
</person-group><article-title>Development of Ligands and Degraders Targeting MAGE-A3</article-title><source>J. Am. Chem. Soc.</source><year>2024</year><volume>146</volume><fpage>24884</fpage><lpage>24891</lpage><pub-id pub-id-type="doi">10.1021/jacs.4c05393</pub-id><pub-id pub-id-type="pmid">39190582</pub-id>
</element-citation></ref><ref id="B20-vaccines-13-00185"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Esfandiary</surname><given-names>A.</given-names></name>
<name><surname>Ghafouri-Fard</surname><given-names>S.</given-names></name>
</person-group><article-title>MAGE-A3: An Immunogenic Target Used in Clinical Practice</article-title><source>Immunotherapy</source><year>2015</year><volume>7</volume><fpage>683</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.2217/imt.15.29</pub-id><pub-id pub-id-type="pmid">26100270</pub-id>
</element-citation></ref><ref id="B21-vaccines-13-00185"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peled</surname><given-names>N.</given-names></name>
<name><surname>Oton</surname><given-names>A.B.</given-names></name>
<name><surname>Hirsch</surname><given-names>F.R.</given-names></name>
<name><surname>Bunn</surname><given-names>P.</given-names></name>
</person-group><article-title>Drug Evaluation MAGE A3 Antigen-Specific Cancer Immunotherapeutic</article-title><source>Immunotherapy</source><year>2009</year><volume>1</volume><fpage>19</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.2217/1750743X.1.1.19</pub-id><pub-id pub-id-type="pmid">20635969</pub-id>
</element-citation></ref><ref id="B22-vaccines-13-00185"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Batchu</surname><given-names>R.B.</given-names></name>
<name><surname>Gruzdyn</surname><given-names>O.</given-names></name>
<name><surname>Potti</surname><given-names>R.B.</given-names></name>
<name><surname>Weaver</surname><given-names>D.W.</given-names></name>
<name><surname>Gruber</surname><given-names>S.A.</given-names></name>
</person-group><article-title>MAGE-A3 with Cell-Penetrating Domain as an Efficient Therapeutic Cancer Vaccine</article-title><source>JAMA Surg.</source><year>2014</year><volume>149</volume><fpage>451</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1001/jamasurg.2013.4113</pub-id><pub-id pub-id-type="pmid">24671426</pub-id>
</element-citation></ref><ref id="B23-vaccines-13-00185"><label>23.</label><element-citation publication-type="gov"><article-title>Study Details|GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Non-Small Cell Lung Cancer|ClinicalTrials.gov</article-title><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT00480025?cond=NCT00480025&#x00026;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT00480025?cond=NCT00480025&#x00026;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-29">(accessed on 29 December 2024)</date-in-citation></element-citation></ref><ref id="B24-vaccines-13-00185"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tyagi</surname><given-names>P.</given-names></name>
<name><surname>Mirakhur</surname><given-names>B.</given-names></name>
</person-group><article-title>MAGRIT: The Largest-Ever Phase Iii Lung Cancer Trial Aims to Establish a Novel Tumor-Specific Approach to Therapy</article-title><source>Clin. Lung Cancer</source><year>2009</year><volume>10</volume><fpage>371</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.3816/CLC.2009.n.052</pub-id><pub-id pub-id-type="pmid">19808198</pub-id>
</element-citation></ref><ref id="B25-vaccines-13-00185"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thomas</surname><given-names>R.</given-names></name>
<name><surname>Al-Khadairi</surname><given-names>G.</given-names></name>
<name><surname>Roelands</surname><given-names>J.</given-names></name>
<name><surname>Hendrickx</surname><given-names>W.</given-names></name>
<name><surname>Dermime</surname><given-names>S.</given-names></name>
<name><surname>Bedognetti</surname><given-names>D.</given-names></name>
<name><surname>Decock</surname><given-names>J.</given-names></name>
</person-group><article-title>NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><elocation-id>947</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.00947</pub-id><pub-id pub-id-type="pmid">29770138</pub-id>
</element-citation></ref><ref id="B26-vaccines-13-00185"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ishihara</surname><given-names>M.</given-names></name>
<name><surname>Kitano</surname><given-names>S.</given-names></name>
<name><surname>Kageyama</surname><given-names>S.</given-names></name>
<name><surname>Miyahara</surname><given-names>Y.</given-names></name>
<name><surname>Yamamoto</surname><given-names>N.</given-names></name>
<name><surname>Kato</surname><given-names>H.</given-names></name>
<name><surname>Mishima</surname><given-names>H.</given-names></name>
<name><surname>Hattori</surname><given-names>H.</given-names></name>
<name><surname>Funakoshi</surname><given-names>T.</given-names></name>
<name><surname>Kojima</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>NY-ESO-1-Specific Redirected T Cells with Endogenous TCR Knockdown Mediate Tumor Response and Cytokine Release Syndrome</article-title><source>J. Immunother. Cancer</source><year>2022</year><volume>10</volume><fpage>e003811</fpage><pub-id pub-id-type="doi">10.1136/jitc-2021-003811</pub-id><pub-id pub-id-type="pmid">35768164</pub-id>
</element-citation></ref><ref id="B27-vaccines-13-00185"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Esfandiary</surname><given-names>A.</given-names></name>
<name><surname>Ghafouri-Fard</surname><given-names>S.</given-names></name>
</person-group><article-title>New York Esophageal Squamous Cell Carcinoma-1 and Cancer Immunotherapy</article-title><source>Immunotherapy</source><year>2015</year><volume>7</volume><fpage>411</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.2217/imt.15.3</pub-id><pub-id pub-id-type="pmid">25917631</pub-id>
</element-citation></ref><ref id="B28-vaccines-13-00185"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Somaiah</surname><given-names>N.</given-names></name>
<name><surname>Block</surname><given-names>M.S.</given-names></name>
<name><surname>Kim</surname><given-names>J.W.</given-names></name>
<name><surname>Shapiro</surname><given-names>G.I.</given-names></name>
<name><surname>Do</surname><given-names>K.T.</given-names></name>
<name><surname>Hwu</surname><given-names>P.</given-names></name>
<name><surname>Eder</surname><given-names>J.P.</given-names></name>
<name><surname>Jones</surname><given-names>R.L.</given-names></name>
<name><surname>Lu</surname><given-names>H.</given-names></name>
<name><surname>Ter Meulen</surname><given-names>J.H.</given-names></name>
<etal/>
</person-group><article-title>First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1</article-title><source>Clin. Cancer Res.</source><year>2019</year><volume>25</volume><fpage>5808</fpage><lpage>5817</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-1025</pub-id><pub-id pub-id-type="pmid">31227504</pub-id>
</element-citation></ref><ref id="B29-vaccines-13-00185"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mahipal</surname><given-names>A.</given-names></name>
<name><surname>Ejadi</surname><given-names>S.</given-names></name>
<name><surname>Gnjatic</surname><given-names>S.</given-names></name>
<name><surname>Kim-Schulze</surname><given-names>S.</given-names></name>
<name><surname>Lu</surname><given-names>H.</given-names></name>
<name><surname>ter Meulen</surname><given-names>J.H.</given-names></name>
<name><surname>Kenney</surname><given-names>R.</given-names></name>
<name><surname>Odunsi</surname><given-names>K.</given-names></name>
</person-group><article-title>First-in-Human Phase 1 Dose-Escalating Trial of G305 in Patients with Advanced Solid Tumors Expressing NY-ESO-1</article-title><source>Cancer Immunol. Immunother.</source><year>2019</year><volume>68</volume><fpage>1211</fpage><lpage>1222</lpage><pub-id pub-id-type="doi">10.1007/s00262-019-02331-x</pub-id><pub-id pub-id-type="pmid">31069460</pub-id>
</element-citation></ref><ref id="B30-vaccines-13-00185"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Supruniuk</surname><given-names>K.</given-names></name>
<name><surname>Radziejewska</surname><given-names>I.</given-names></name>
</person-group><article-title>MUC1 Is an Oncoprotein with a Significant Role in Apoptosis (Review)</article-title><source>Int. J. Oncol.</source><year>2021</year><volume>59</volume><fpage>68</fpage><pub-id pub-id-type="doi">10.3892/ijo.2021.5248</pub-id><pub-id pub-id-type="pmid">34278474</pub-id>
</element-citation></ref><ref id="B31-vaccines-13-00185"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nath</surname><given-names>S.</given-names></name>
<name><surname>Mukherjee</surname><given-names>P.</given-names></name>
</person-group><article-title>MUC1: A Multifaceted Oncoprotein with a Key Role in Cancer Progression</article-title><source>Trends Mol. Med.</source><year>2014</year><volume>20</volume><fpage>332</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2014.02.007</pub-id><pub-id pub-id-type="pmid">24667139</pub-id>
</element-citation></ref><ref id="B32-vaccines-13-00185"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reck</surname><given-names>M.</given-names></name>
</person-group><article-title>What Future Opportunities May Immuno-Oncology Provide for Improving the Treatment of Patients with Lung Cancer?</article-title><source>Ann. Oncol.</source><year>2012</year><volume>23</volume><fpage>viii28</fpage><lpage>viii34</lpage><pub-id pub-id-type="doi">10.1093/annonc/mds260</pub-id><pub-id pub-id-type="pmid">22918925</pub-id>
</element-citation></ref><ref id="B33-vaccines-13-00185"><label>33.</label><element-citation publication-type="gov"><article-title>Study Details|Anti-Cancer MUC1-Specific Immunotherapy for Unresectable Stage III Non-Small Cell Lung Cancer|ClinicalTrials.gov</article-title><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT01731587?cond=%20Tecemotide%20(L-BLP25)&#x00026;page=2&#x00026;rank=14" ext-link-type="uri">https://clinicaltrials.gov/study/NCT01731587?cond=%20Tecemotide%20(L-BLP25)&#x00026;page=2&#x00026;rank=14</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-29">(accessed on 29 November 2024)</date-in-citation></element-citation></ref><ref id="B34-vaccines-13-00185"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patel</surname><given-names>J.D.</given-names></name>
<name><surname>Lee</surname><given-names>J.W.</given-names></name>
<name><surname>Carbone</surname><given-names>D.P.</given-names></name>
<name><surname>Wagner</surname><given-names>H.</given-names></name>
<name><surname>Shanker</surname><given-names>A.</given-names></name>
<name><surname>de Aquino</surname><given-names>M.T.P.</given-names></name>
<name><surname>Horn</surname><given-names>L.</given-names></name>
<name><surname>Johnson</surname><given-names>M.L.</given-names></name>
<name><surname>Gerber</surname><given-names>D.E.</given-names></name>
<name><surname>Liu</surname><given-names>J.J.</given-names></name>
<etal/>
</person-group><article-title>Phase II Study of Immunotherapy with Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non&#x02013;Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508)</article-title><source>Clin. Lung Cancer</source><year>2020</year><volume>21</volume><fpage>520</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1016/j.cllc.2020.06.007</pub-id><pub-id pub-id-type="pmid">32807654</pub-id>
</element-citation></ref><ref id="B35-vaccines-13-00185"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Butts</surname><given-names>C.</given-names></name>
<name><surname>Socinski</surname><given-names>M.A.</given-names></name>
<name><surname>Mitchell</surname><given-names>P.L.</given-names></name>
<name><surname>Thatcher</surname><given-names>N.</given-names></name>
<name><surname>Havel</surname><given-names>L.</given-names></name>
<name><surname>Krzakowski</surname><given-names>M.</given-names></name>
<name><surname>Nawrocki</surname><given-names>S.</given-names></name>
<name><surname>Ciuleanu</surname><given-names>T.E.</given-names></name>
<name><surname>Bosqu&#x000e9;e</surname><given-names>L.</given-names></name>
<name><surname>Trigo</surname><given-names>J.M.</given-names></name>
<etal/>
</person-group><article-title>Tecemotide (L-BLP25) versus Placebo after Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer (START): A Randomised, Double-Blind, Phase 3 Trial</article-title><source>Lancet Oncol.</source><year>2014</year><volume>15</volume><fpage>59</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(13)70510-2</pub-id><pub-id pub-id-type="pmid">24331154</pub-id>
</element-citation></ref><ref id="B36-vaccines-13-00185"><label>36.</label><element-citation publication-type="gov"><article-title>Study Details|Tecemotide Following Concurrent Chemo-Radiotherapy for Non-Small Cell Lung Cancer|ClinicalTrials.gov</article-title><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT02049151?cond=NCT02049151&#x00026;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT02049151?cond=NCT02049151&#x00026;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-29">(accessed on 29 November 2024)</date-in-citation></element-citation></ref><ref id="B37-vaccines-13-00185"><label>37.</label><element-citation publication-type="gov"><article-title>Record History|NCT01015443|ClinicalTrials.gov</article-title><comment>Available online: <ext-link xlink:href="https://www.clinicaltrials.gov/study/NCT01015443?term=INSPIRE%20tecemotide&#x00026;rank=1&#x00026;tab=history" ext-link-type="uri">https://www.clinicaltrials.gov/study/NCT01015443?term=INSPIRE%20tecemotide&#x00026;rank=1&#x00026;tab=history</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-29">(accessed on 29 November 2024)</date-in-citation></element-citation></ref><ref id="B38-vaccines-13-00185"><label>38.</label><element-citation publication-type="webpage"><article-title>Merck KGaA Discontinues Clinical Development Program of Tecemotide as a Monotherapy in Stage III Non-Small Cell Lung Cancer</article-title><comment>Available online: <ext-link xlink:href="https://www.prnewswire.com/news-releases/merck-kgaa-discontinues-clinical-development-program-of-tecemotide-as-a-monotherapy-in-stage-iii-non-small-cell-lung-cancer-274891191.html" ext-link-type="uri">https://www.prnewswire.com/news-releases/merck-kgaa-discontinues-clinical-development-program-of-tecemotide-as-a-monotherapy-in-stage-iii-non-small-cell-lung-cancer-274891191.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-22">(accessed on 22 December 2024)</date-in-citation></element-citation></ref><ref id="B39-vaccines-13-00185"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pagliari</surname><given-names>S.</given-names></name>
<name><surname>Dema</surname><given-names>B.</given-names></name>
<name><surname>Sanchez-Martinez</surname><given-names>A.</given-names></name>
<name><surname>Montalvo Zurbia-Flores</surname><given-names>G.</given-names></name>
<name><surname>Rollier</surname><given-names>C.S.</given-names></name>
</person-group><article-title>DNA Vaccines: History, Molecular Mechanisms and Future Perspectives</article-title><source>J. Mol. Biol.</source><year>2023</year><volume>435</volume><elocation-id>168297</elocation-id><pub-id pub-id-type="doi">10.1016/j.jmb.2023.168297</pub-id><pub-id pub-id-type="pmid">37797831</pub-id>
</element-citation></ref><ref id="B40-vaccines-13-00185"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lopes</surname><given-names>A.</given-names></name>
<name><surname>Vandermeulen</surname><given-names>G.</given-names></name>
<name><surname>Pr&#x000e9;at</surname><given-names>V.</given-names></name>
</person-group><article-title>Cancer DNA Vaccines: Current Preclinical and Clinical Developments and Future Perspectives</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2019</year><volume>38</volume><fpage>146</fpage><pub-id pub-id-type="doi">10.1186/s13046-019-1154-7</pub-id><pub-id pub-id-type="pmid">30953535</pub-id>
</element-citation></ref><ref id="B41-vaccines-13-00185"><label>41.</label><element-citation publication-type="gov"><article-title>Search for: recMAGE-A3|Card Results|ClinicalTrials.gov</article-title><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/search?cond=recMAGE-A3%20%20" ext-link-type="uri">https://clinicaltrials.gov/search?cond=recMAGE-A3%20%20</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-29">(accessed on 29 November 2024)</date-in-citation></element-citation></ref><ref id="B42-vaccines-13-00185"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sasso</surname><given-names>E.</given-names></name>
<name><surname>D&#x02019;Alise</surname><given-names>A.M.</given-names></name>
<name><surname>Zambrano</surname><given-names>N.</given-names></name>
<name><surname>Scarselli</surname><given-names>E.</given-names></name>
<name><surname>Folgori</surname><given-names>A.</given-names></name>
<name><surname>Nicosia</surname><given-names>A.</given-names></name>
</person-group><article-title>New Viral Vectors for Infectious Diseases and Cancer</article-title><source>Semin. Immunol.</source><year>2020</year><volume>50</volume><fpage>101430</fpage><pub-id pub-id-type="doi">10.1016/j.smim.2020.101430</pub-id><pub-id pub-id-type="pmid">33262065</pub-id>
</element-citation></ref><ref id="B43-vaccines-13-00185"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McCann</surname><given-names>N.</given-names></name>
<name><surname>O&#x02019;Connor</surname><given-names>D.</given-names></name>
<name><surname>Lambe</surname><given-names>T.</given-names></name>
<name><surname>Pollard</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Viral Vector Vaccines</article-title><source>Curr. Opin. Immunol.</source><year>2022</year><volume>77</volume><fpage>102210</fpage><pub-id pub-id-type="doi">10.1016/j.coi.2022.102210</pub-id><pub-id pub-id-type="pmid">35643023</pub-id>
</element-citation></ref><ref id="B44-vaccines-13-00185"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Liang</surname><given-names>B.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Feng</surname><given-names>N.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>T.</given-names></name>
<name><surname>Yan</surname><given-names>F.</given-names></name>
<name><surname>Yang</surname><given-names>S.</given-names></name>
<name><surname>Xia</surname><given-names>X.</given-names></name>
</person-group><article-title>Viral Vectored Vaccines: Design, Development, Preventive and Therapeutic Applications in Human Diseases</article-title><source>Signal Transduct. Target. Ther.</source><year>2023</year><volume>8</volume><fpage>149</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01408-5</pub-id><pub-id pub-id-type="pmid">37029123</pub-id>
</element-citation></ref><ref id="B45-vaccines-13-00185"><label>45.</label><element-citation publication-type="gov"><article-title>Study Details|A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined with the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients with Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)|ClinicalTrials.gov</article-title><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT03353675?cond=TG4010&#x00026;rank=5" ext-link-type="uri">https://clinicaltrials.gov/study/NCT03353675?cond=TG4010&#x00026;rank=5</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-30">(accessed on 30 November 2024)</date-in-citation></element-citation></ref><ref id="B46-vaccines-13-00185"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ramlau</surname><given-names>R.</given-names></name>
<name><surname>Quoix</surname><given-names>E.</given-names></name>
<name><surname>Rolski</surname><given-names>J.</given-names></name>
<name><surname>Pless</surname><given-names>M.</given-names></name>
<name><surname>Lena</surname><given-names>H.</given-names></name>
<name><surname>L&#x000e9;vy</surname><given-names>E.</given-names></name>
<name><surname>Krzakowski</surname><given-names>M.</given-names></name>
<name><surname>Hess</surname><given-names>D.</given-names></name>
<name><surname>Tartour</surname><given-names>E.</given-names></name>
<name><surname>Chenard</surname><given-names>M.P.</given-names></name>
<etal/>
</person-group><article-title>A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-Small Cell Lung Cancer</article-title><source>J. Thorac. Oncol.</source><year>2008</year><volume>3</volume><fpage>735</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1097/JTO.0b013e31817c6b4f</pub-id><pub-id pub-id-type="pmid">18594319</pub-id>
</element-citation></ref><ref id="B47-vaccines-13-00185"><label>47.</label><element-citation publication-type="gov"><article-title>Researcher View|Immunization of Patients with Non Small Cell Lung Cancer (NSCLC)|ClinicalTrials.gov</article-title><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT00793208?intr=NCT00793208&#x00026;rank=1%27&#x00026;tab=table" ext-link-type="uri">https://clinicaltrials.gov/study/NCT00793208?intr=NCT00793208&#x00026;rank=1%27&#x00026;tab=table</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-30">(accessed on 30 November 2024)</date-in-citation></element-citation></ref><ref id="B48-vaccines-13-00185"><label>48.</label><element-citation publication-type="gov"><article-title>Definition of Genetically-Modified MAGE-A3-Expressing MG1 Maraba Virus Vaccine&#x02014;NCI Drug Dictionary&#x02014;NCI</article-title><comment>Available online: <ext-link xlink:href="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/genetically-modified-mage-a3-expressing-mg1-maraba-virus-vaccine" ext-link-type="uri">https://www.cancer.gov/publications/dictionaries/cancer-drug/def/genetically-modified-mage-a3-expressing-mg1-maraba-virus-vaccine</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-30">(accessed on 30 November 2024)</date-in-citation></element-citation></ref><ref id="B49-vaccines-13-00185"><label>49.</label><element-citation publication-type="gov"><article-title>Definition of MAGE-A3-Expressing Adenovirus Type5 Vaccine&#x02014;NCI Drug Dictionary&#x02014;NCI</article-title><comment>Available online: <ext-link xlink:href="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/mage-a3-expressing-adenovirus-type-5-vaccine" ext-link-type="uri">https://www.cancer.gov/publications/dictionaries/cancer-drug/def/mage-a3-expressing-adenovirus-type-5-vaccine</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-30">(accessed on 30 November 2024)</date-in-citation></element-citation></ref><ref id="B50-vaccines-13-00185"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pol</surname><given-names>J.G.</given-names></name>
<name><surname>Acuna</surname><given-names>S.A.</given-names></name>
<name><surname>Yadollahi</surname><given-names>B.</given-names></name>
<name><surname>Tang</surname><given-names>N.</given-names></name>
<name><surname>Stephenson</surname><given-names>K.B.</given-names></name>
<name><surname>Atherton</surname><given-names>M.J.</given-names></name>
<name><surname>Hanwell</surname><given-names>D.</given-names></name>
<name><surname>El-Warrak</surname><given-names>A.</given-names></name>
<name><surname>Goldstein</surname><given-names>A.</given-names></name>
<name><surname>Moloo</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Preclinical Evaluation of a MAGE-A3 Vaccination Utilizing the Oncolytic Maraba Virus Currently in First-in-Human Trials</article-title><source>Oncoimmunology</source><year>2019</year><volume>8</volume><fpage>e1512329</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2018.1512329</pub-id><pub-id pub-id-type="pmid">30546947</pub-id>
</element-citation></ref><ref id="B51-vaccines-13-00185"><label>51.</label><element-citation publication-type="gov"><article-title>Study Details|MG1 Maraba/MAGE-A3, with and Without Adenovirus Vaccine with Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours|ClinicalTrials.gov</article-title><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT02285816?intr=NCT02285816&#x00026;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT02285816?intr=NCT02285816&#x00026;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-30">(accessed on 30 November 2024)</date-in-citation></element-citation></ref><ref id="B52-vaccines-13-00185"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fu</surname><given-names>C.</given-names></name>
<name><surname>Ma</surname><given-names>T.</given-names></name>
<name><surname>Zhou</surname><given-names>L.</given-names></name>
<name><surname>Mi</surname><given-names>Q.S.</given-names></name>
<name><surname>Jiang</surname><given-names>A.</given-names></name>
</person-group><article-title>Dendritic Cell-Based Vaccines Against Cancer: Challenges, Advances and Future Opportunities</article-title><source>Immunol. Investig.</source><year>2022</year><volume>51</volume><fpage>2133</fpage><lpage>2158</lpage><pub-id pub-id-type="doi">10.1080/08820139.2022.2109486</pub-id><pub-id pub-id-type="pmid">35946383</pub-id>
</element-citation></ref><ref id="B53-vaccines-13-00185"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mosca</surname><given-names>P.J.</given-names></name>
<name><surname>Hobeika</surname><given-names>A.C.</given-names></name>
<name><surname>Clay</surname><given-names>T.M.</given-names></name>
<name><surname>Morse</surname><given-names>M.A.</given-names></name>
<name><surname>Lyerly</surname><given-names>H.K.</given-names></name>
</person-group><article-title>Dendritic Cell Vaccines</article-title><source>Front. Biosci.</source><year>2007</year><volume>12</volume><fpage>4050</fpage><lpage>4060</lpage><pub-id pub-id-type="doi">10.2741/2371</pub-id><pub-id pub-id-type="pmid">17485358</pub-id>
</element-citation></ref><ref id="B54-vaccines-13-00185"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sabado</surname><given-names>R.L.</given-names></name>
<name><surname>Balan</surname><given-names>S.</given-names></name>
<name><surname>Bhardwaj</surname><given-names>N.</given-names></name>
</person-group><article-title>Dendritic Cell-Based Immunotherapy</article-title><source>Cell Res.</source><year>2017</year><volume>27</volume><fpage>74</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1038/cr.2016.157</pub-id><pub-id pub-id-type="pmid">28025976</pub-id>
</element-citation></ref><ref id="B55-vaccines-13-00185"><label>55.</label><element-citation publication-type="gov"><article-title>Study Details|Vaccine Therapy in Treating Patients with Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer|ClinicalTrials.gov</article-title><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT00601094?cond=NCT00601094%C2%A0&#x00026;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT00601094?cond=NCT00601094%C2%A0&#x00026;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-30">(accessed on 30 November 2024)</date-in-citation></element-citation></ref><ref id="B56-vaccines-13-00185"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>J.M.</given-names></name>
<name><surname>Lee</surname><given-names>M.H.</given-names></name>
<name><surname>Garon</surname><given-names>E.</given-names></name>
<name><surname>Goldman</surname><given-names>J.W.</given-names></name>
<name><surname>Salehi-Rad</surname><given-names>R.</given-names></name>
<name><surname>Baratelli</surname><given-names>F.E.</given-names></name>
<name><surname>Schaue</surname><given-names>D.</given-names></name>
<name><surname>Wang</surname><given-names>G.</given-names></name>
<name><surname>Rosen</surname><given-names>F.</given-names></name>
<name><surname>Yanagawa</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Phase I Trial of Intratumoral Injection of CCL21 Gene&#x02013;Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-Cell Infiltration</article-title><source>Clin. Cancer Res.</source><year>2017</year><volume>23</volume><fpage>4556</fpage><lpage>4568</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-2821</pub-id><pub-id pub-id-type="pmid">28468947</pub-id>
</element-citation></ref><ref id="B57-vaccines-13-00185"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Lisberg</surname><given-names>A.</given-names></name>
<name><surname>Salehi-Rad</surname><given-names>R.</given-names></name>
<name><surname>Lee</surname><given-names>J.</given-names></name>
<name><surname>Tran</surname><given-names>L.M.</given-names></name>
<name><surname>Krysan</surname><given-names>K.</given-names></name>
<name><surname>Lim</surname><given-names>R.</given-names></name>
<name><surname>Dumitras</surname><given-names>C.</given-names></name>
<name><surname>Jing</surname><given-names>Z.</given-names></name>
<name><surname>Oh</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Abstract CT219: Phase I Trial of in Situ Vaccination with Autologous CCL21 Gene-Modified Dendritic Cells (CCL21-DC) Combined with Pembrolizumab for Advanced Non-Small Cell Lung Cancer (NSCLC)</article-title><source>Cancer Res.</source><year>2022</year><volume>82</volume><issue>(Suppl. S12)</issue><fpage>CT219</fpage><pub-id pub-id-type="doi">10.1158/1538-7445.AM2022-CT219</pub-id></element-citation></ref><ref id="B58-vaccines-13-00185"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roy</surname><given-names>S.</given-names></name>
<name><surname>Sethi</surname><given-names>T.K.</given-names></name>
<name><surname>Taylor</surname><given-names>D.</given-names></name>
<name><surname>Kim</surname><given-names>Y.J.</given-names></name>
<name><surname>Johnson</surname><given-names>D.B.</given-names></name>
</person-group><article-title>Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside</article-title><source>J. Leukoc. Biol.</source><year>2020</year><volume>108</volume><fpage>1455</fpage><lpage>1489</lpage><pub-id pub-id-type="pmid">32557857</pub-id>
</element-citation></ref><ref id="B59-vaccines-13-00185"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moingeon</surname><given-names>P.</given-names></name>
</person-group><article-title>Cancer Vaccines</article-title><source>Vaccine</source><year>2001</year><volume>19</volume><fpage>1305</fpage><lpage>1326</lpage><comment>Available online: <ext-link xlink:href="www.elsevier.com/locate/vaccine" ext-link-type="uri">www.elsevier.com/locate/vaccine</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-15">(accessed on 15 December 2024)</date-in-citation><pub-id pub-id-type="doi">10.1016/S0264-410X(00)00372-8</pub-id><pub-id pub-id-type="pmid">11163653</pub-id>
</element-citation></ref><ref id="B60-vaccines-13-00185"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Melenhorst</surname><given-names>J.J.</given-names></name>
<name><surname>Barrett</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Tumor Vaccines and Beyond</article-title><source>Cytotherapy</source><year>2011</year><volume>13</volume><fpage>8</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.3109/14653249.2010.530649</pub-id><pub-id pub-id-type="pmid">21067312</pub-id>
</element-citation></ref><ref id="B61-vaccines-13-00185"><label>61.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Thompson</surname><given-names>P.L.</given-names></name>
<name><surname>Dessureault</surname><given-names>S.</given-names></name>
<name><surname>Shurin</surname><given-names>M.R.</given-names></name>
<name><surname>Smolkin</surname><given-names>Y.S.</given-names></name>
</person-group><source>Tumor Vaccines</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2007</year><fpage>344</fpage><date-in-citation content-type="access-date" iso-8601-date="2024-12-18">(accessed on 18 December 2024)</date-in-citation></element-citation></ref><ref id="B62-vaccines-13-00185"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Giaccone</surname><given-names>G.</given-names></name>
<name><surname>Bazhenova</surname><given-names>L.A.</given-names></name>
<name><surname>Nemunaitis</surname><given-names>J.</given-names></name>
<name><surname>Tan</surname><given-names>M.</given-names></name>
<name><surname>Juh&#x000e1;sz</surname><given-names>E.</given-names></name>
<name><surname>Ramlau</surname><given-names>R.</given-names></name>
<name><surname>Van Den Heuvel</surname><given-names>M.M.</given-names></name>
<name><surname>Lal</surname><given-names>R.</given-names></name>
<name><surname>Kloecker</surname><given-names>G.H.</given-names></name>
<name><surname>Eaton</surname><given-names>K.D.</given-names></name>
<etal/>
</person-group><article-title>A Phase III Study of Belagenpumatucel-L, an Allogeneic Tumour Cell Vaccine, as Maintenance Therapy for Non-Small Cell Lung Cancer</article-title><source>Eur. J. Cancer</source><year>2015</year><volume>51</volume><fpage>2321</fpage><lpage>2329</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2015.07.035</pub-id><pub-id pub-id-type="pmid">26283035</pub-id>
</element-citation></ref><ref id="B63-vaccines-13-00185"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Creelan</surname><given-names>B.C.</given-names></name>
<name><surname>Antonia</surname><given-names>S.</given-names></name>
<name><surname>Noyes</surname><given-names>D.</given-names></name>
<name><surname>Hunter</surname><given-names>T.B.</given-names></name>
<name><surname>Simon</surname><given-names>G.R.</given-names></name>
<name><surname>Bepler</surname><given-names>G.</given-names></name>
<name><surname>Williams</surname><given-names>C.C.</given-names></name>
<name><surname>Tanvetyanon</surname><given-names>T.</given-names></name>
<name><surname>Haura</surname><given-names>E.B.</given-names></name>
<name><surname>Schell</surname><given-names>M.J.</given-names></name>
<etal/>
</person-group><article-title>Phase II Trial of a GM-CSF-Producing and CD40L-Expressing Bystander Cell Line Combined with an Allogeneic Tumor Cell-Based Vaccine for Refractory Lung Adenocarcinoma</article-title><source>J. Immunother.</source><year>2013</year><volume>36</volume><fpage>442</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1097/CJI.0b013e3182a80237</pub-id><pub-id pub-id-type="pmid">23994887</pub-id>
</element-citation></ref><ref id="B64-vaccines-13-00185"><label>64.</label><element-citation publication-type="gov"><article-title>Study Details|Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer|ClinicalTrials.gov</article-title><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT02460367?cond=NCT02460367%C2%A0&#x00026;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT02460367?cond=NCT02460367%C2%A0&#x00026;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-30">(accessed on 30 November 2024)</date-in-citation></element-citation></ref><ref id="B65-vaccines-13-00185"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Govindan</surname><given-names>R.</given-names></name>
<name><surname>Morris</surname><given-names>J.C.</given-names></name>
<name><surname>Rossi</surname><given-names>G.R.</given-names></name>
<name><surname>Vahanian</surname><given-names>N.N.</given-names></name>
<name><surname>Link</surname><given-names>C.J.</given-names></name>
</person-group><article-title>NLG-0301: An Open-Label, Randomized Phase 2B Active Control Study of Second-Line Tergenpumatucel-L Immunotherapy versus Docetaxel in Patients with Progressive or Relapsed Non-Small Cell Lung Cancer (NSCLC)</article-title><source>J. Clin. Oncol.</source><year>2014</year><volume>32</volume><issue>(Suppl. S15)</issue><fpage>TPS8133</fpage><pub-id pub-id-type="doi">10.1200/jco.2014.32.15_suppl.tps8133</pub-id></element-citation></ref><ref id="B66-vaccines-13-00185"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morgensztern</surname><given-names>D.</given-names></name>
<name><surname>Bazhenova</surname><given-names>L.</given-names></name>
<name><surname>Waqar</surname><given-names>S.N.</given-names></name>
<name><surname>McDermott</surname><given-names>L.</given-names></name>
<name><surname>Hutchins</surname><given-names>J.</given-names></name>
<name><surname>Harb</surname><given-names>W.A.</given-names></name>
<name><surname>Velcheti</surname><given-names>V.</given-names></name>
<name><surname>Cohen</surname><given-names>R.B.</given-names></name>
</person-group><article-title>Viagenpumatucel-L (HS-110) plus Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)</article-title><source>J. Clin. Oncol.</source><year>2019</year><volume>37</volume><issue>(Suppl. S8)</issue><fpage>101</fpage><pub-id pub-id-type="doi">10.1200/JCO.2019.37.8_suppl.101</pub-id></element-citation></ref><ref id="B67-vaccines-13-00185"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Katagiri</surname><given-names>T.</given-names></name>
<name><surname>Shiobara</surname><given-names>S.</given-names></name>
<name><surname>Nakao</surname><given-names>S.</given-names></name>
<name><surname>Wakano</surname><given-names>M.</given-names></name>
<name><surname>Muranaka</surname><given-names>E.</given-names></name>
<name><surname>Kuba</surname><given-names>N.</given-names></name>
<name><surname>Furukawa</surname><given-names>T.</given-names></name>
<name><surname>Tsukada</surname><given-names>J.</given-names></name>
<name><surname>Takeda</surname><given-names>H.</given-names></name>
<name><surname>Aizawa</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Mismatch of Minor Histocompatibility Antigen Contributes to a Graft-versus-Leukemia Effect Rather than to Acute GVHD, Resulting in Long-Term Survival after HLA-Identical Stem Cell Transplantation in Japan</article-title><source>Bone Marrow Transpl.</source><year>2006</year><volume>38</volume><fpage>681</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1038/sj.bmt.1705506</pub-id><pub-id pub-id-type="pmid">16980988</pub-id>
</element-citation></ref><ref id="B68-vaccines-13-00185"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Satoh</surname><given-names>E.</given-names></name>
<name><surname>Naganuma</surname><given-names>H.</given-names></name>
<name><surname>Sasaki</surname><given-names>A.</given-names></name>
<name><surname>Nagasaka</surname><given-names>M.</given-names></name>
<name><surname>Ogata</surname><given-names>H.</given-names></name>
<name><surname>Nukui</surname><given-names>H.</given-names></name>
</person-group><article-title>Effect of Irradiation on Transforming Growth Factor-Beta Secretion by Malignant Glioma Cells</article-title><source>J. Neurooncol.</source><year>1997</year><volume>33</volume><fpage>195</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1023/A:1005791621265</pub-id><pub-id pub-id-type="pmid">9195490</pub-id>
</element-citation></ref><ref id="B69-vaccines-13-00185"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Klopp</surname><given-names>A.H.</given-names></name>
<name><surname>Spaeth</surname><given-names>E.L.</given-names></name>
<name><surname>Dembinski</surname><given-names>J.L.</given-names></name>
<name><surname>Woodward</surname><given-names>W.A.</given-names></name>
<name><surname>Munshi</surname><given-names>A.</given-names></name>
<name><surname>Meyn</surname><given-names>R.E.</given-names></name>
<name><surname>Cox</surname><given-names>J.D.</given-names></name>
<name><surname>Andreeff</surname><given-names>M.</given-names></name>
<name><surname>Marini</surname><given-names>F.C.</given-names></name>
</person-group><article-title>Tumor Irradiation Increases the Recruitment of Circulating Mesenchymal Stem Cells into the Tumor Microenvironment</article-title><source>Cancer Res.</source><year>2007</year><volume>67</volume><fpage>11687</fpage><lpage>11695</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-1406</pub-id><pub-id pub-id-type="pmid">18089798</pub-id>
</element-citation></ref><ref id="B70-vaccines-13-00185"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vishweshwaraiah</surname><given-names>Y.L.</given-names></name>
<name><surname>Dokholyan</surname><given-names>N.V.</given-names></name>
</person-group><article-title>MRNA Vaccines for Cancer Immunotherapy</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>1029069</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.1029069</pub-id><pub-id pub-id-type="pmid">36591226</pub-id>
</element-citation></ref><ref id="B71-vaccines-13-00185"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Teo</surname><given-names>S.P.</given-names></name>
</person-group><article-title>Review of COVID-19 MRNA Vaccines: BNT162b2 and MRNA-1273</article-title><source>J. Pharm. Pract.</source><year>2022</year><volume>35</volume><fpage>947</fpage><lpage>951</lpage><pub-id pub-id-type="doi">10.1177/08971900211009650</pub-id><pub-id pub-id-type="pmid">33840294</pub-id>
</element-citation></ref><ref id="B72-vaccines-13-00185"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rosa</surname><given-names>S.S.</given-names></name>
<name><surname>Prazeres</surname><given-names>D.M.F.</given-names></name>
<name><surname>Azevedo</surname><given-names>A.M.</given-names></name>
<name><surname>Marques</surname><given-names>M.P.C.</given-names></name>
</person-group><article-title>MRNA Vaccines Manufacturing: Challenges and Bottlenecks</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><fpage>2190</fpage><lpage>2200</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.03.038</pub-id><pub-id pub-id-type="pmid">33771389</pub-id>
</element-citation></ref><ref id="B73-vaccines-13-00185"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lorentzen</surname><given-names>C.L.</given-names></name>
<name><surname>Haanen</surname><given-names>J.B.</given-names></name>
<name><surname>Met</surname><given-names>&#x000d6;.</given-names></name>
<name><surname>Svane</surname><given-names>I.M.</given-names></name>
</person-group><article-title>Clinical Advances and Ongoing Trials of MRNA Vaccines for Cancer Treatment</article-title><source>Lancet Oncol.</source><year>2022</year><volume>23</volume><fpage>e450</fpage><lpage>e458</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(22)00372-2</pub-id><pub-id pub-id-type="pmid">36174631</pub-id>
</element-citation></ref><ref id="B74-vaccines-13-00185"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yaremenko</surname><given-names>A.V.</given-names></name>
<name><surname>Khan</surname><given-names>M.M.</given-names></name>
<name><surname>Zhen</surname><given-names>X.</given-names></name>
<name><surname>Tang</surname><given-names>Y.</given-names></name>
<name><surname>Tao</surname><given-names>W.</given-names></name>
</person-group><article-title>Clinical Advances of MRNA Vaccines for Cancer Immunotherapy</article-title><source>Med</source><year>2025</year><volume>6</volume><fpage>100562</fpage><pub-id pub-id-type="doi">10.1016/j.medj.2024.11.015</pub-id><pub-id pub-id-type="pmid">39798545</pub-id>
</element-citation></ref><ref id="B75-vaccines-13-00185"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>&#x000d6;ven</surname><given-names>B.B.</given-names></name>
<name><surname>Baz</surname><given-names>D.V.</given-names></name>
<name><surname>Wolf</surname><given-names>J.</given-names></name>
<name><surname>Ates</surname><given-names>O.</given-names></name>
<name><surname>G&#x000f6;ker</surname><given-names>E.</given-names></name>
<name><surname>Br&#x000fc;ck</surname><given-names>P.</given-names></name>
<name><surname>Wenger</surname><given-names>M.</given-names></name>
<name><surname>Munshi</surname><given-names>N.</given-names></name>
<name><surname>Tsyhankova</surname><given-names>I.</given-names></name>
<name><surname>Tsyhankova</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>Abstract CT051: Preliminary Results from LuCa-MERIT-1, a First-in-Human Phase I Trial Evaluating the Fixed Antigen MRNA Vaccine BNT116 + Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer</article-title><source>Cancer Res.</source><year>2024</year><volume>84</volume><issue>(Suppl. S7)</issue><fpage>CT051</fpage><pub-id pub-id-type="doi">10.1158/1538-7445.AM2024-CT051</pub-id></element-citation></ref><ref id="B76-vaccines-13-00185"><label>76.</label><element-citation publication-type="gov"><article-title>Study Details|A Study of Pembrolizumab (MK-3475) with or Without V940 in Participants with Non-Small Cell Lung Cancer (V940-009/INTerpath-009)|ClinicalTrials.gov</article-title><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT06623422?cond=V940&#x00026;rank=5" ext-link-type="uri">https://clinicaltrials.gov/study/NCT06623422?cond=V940&#x00026;rank=5</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-30">(accessed on 30 November 2024)</date-in-citation></element-citation></ref><ref id="B77-vaccines-13-00185"><label>77.</label><element-citation publication-type="gov"><article-title>Study Details|A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants with Non-small Cell Lung Cancer (V940-002)|ClinicalTrials.gov</article-title><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT06077760?cond=V940&#x00026;rank=6" ext-link-type="uri">https://clinicaltrials.gov/study/NCT06077760?cond=V940&#x00026;rank=6</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-30">(accessed on 30 November 2024)</date-in-citation></element-citation></ref><ref id="B78-vaccines-13-00185"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Su</surname><given-names>S.</given-names></name>
<name><surname>Chen</surname><given-names>F.</given-names></name>
<name><surname>Xu</surname><given-names>M.</given-names></name>
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
</person-group><article-title>Recent Advances in Neoantigen Vaccines for Treating Non-Small Cell Lung Cancer</article-title><source>Thorac. Cancer</source><year>2023</year><volume>14</volume><fpage>3361</fpage><lpage>3368</lpage><pub-id pub-id-type="doi">10.1111/1759-7714.15126</pub-id><pub-id pub-id-type="pmid">37905603</pub-id>
</element-citation></ref><ref id="B79-vaccines-13-00185"><label>79.</label><element-citation publication-type="gov"><article-title>Study Details|Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients with Advanced Esophageal Cancer and Non-Small Cell Lung Cancer|ClinicalTrials.gov</article-title><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/search?cond=NCT03908671" ext-link-type="uri">https://clinicaltrials.gov/search?cond=NCT03908671</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-26">(accessed on 26 January 2025)</date-in-citation></element-citation></ref><ref id="B80-vaccines-13-00185"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thai</surname><given-names>A.A.</given-names></name>
<name><surname>Solomon</surname><given-names>B.J.</given-names></name>
<name><surname>Sequist</surname><given-names>L.V.</given-names></name>
<name><surname>Gainor</surname><given-names>J.F.</given-names></name>
<name><surname>Heist</surname><given-names>R.S.</given-names></name>
</person-group><article-title>Lung Cancer</article-title><source>Lancet</source><year>2021</year><volume>398</volume><fpage>535</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00312-3</pub-id><pub-id pub-id-type="pmid">34273294</pub-id>
</element-citation></ref><ref id="B81-vaccines-13-00185"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>Q.</given-names></name>
</person-group><article-title>Emerging Therapies for Small Cell Lung Cancer</article-title><source>J. Hematol. Oncol.</source><year>2019</year><volume>12</volume><fpage>47</fpage><pub-id pub-id-type="doi">10.1186/s13045-019-0736-3</pub-id><pub-id pub-id-type="pmid">31046803</pub-id>
</element-citation></ref><ref id="B82-vaccines-13-00185"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
<name><surname>Saxena</surname><given-names>A.</given-names></name>
<name><surname>Giaccone</surname><given-names>G.</given-names></name>
</person-group><article-title>Advancements in Small Cell Lung Cancer</article-title><source>Semin. Cancer Biol.</source><year>2023</year><volume>93</volume><fpage>123</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2023.05.008</pub-id><pub-id pub-id-type="pmid">37236329</pub-id>
</element-citation></ref><ref id="B83-vaccines-13-00185"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Horn</surname><given-names>L.</given-names></name>
<name><surname>Mansfield</surname><given-names>A.S.</given-names></name>
<name><surname>Szcz&#x00119;sna</surname><given-names>A.</given-names></name>
<name><surname>Havel</surname><given-names>L.</given-names></name>
<name><surname>Krzakowski</surname><given-names>M.</given-names></name>
<name><surname>Hochmair</surname><given-names>M.J.</given-names></name>
<name><surname>Huemer</surname><given-names>F.</given-names></name>
<name><surname>Losonczy</surname><given-names>G.</given-names></name>
<name><surname>Johnson</surname><given-names>M.L.</given-names></name>
<name><surname>Nishio</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer</article-title><source>N. Engl. J. Med.</source><year>2018</year><volume>379</volume><fpage>2220</fpage><lpage>2229</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1809064</pub-id><pub-id pub-id-type="pmid">30280641</pub-id>
</element-citation></ref><ref id="B84-vaccines-13-00185"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ahn</surname><given-names>M.-J.</given-names></name>
<name><surname>Cho</surname><given-names>B.C.</given-names></name>
<name><surname>Felip</surname><given-names>E.</given-names></name>
<name><surname>Korantzis</surname><given-names>I.</given-names></name>
<name><surname>Ohashi</surname><given-names>K.</given-names></name>
<name><surname>Majem</surname><given-names>M.</given-names></name>
<name><surname>Juan-Vidal</surname><given-names>O.</given-names></name>
<name><surname>Handzhiev</surname><given-names>S.</given-names></name>
<name><surname>Izumi</surname><given-names>H.</given-names></name>
<name><surname>Lee</surname><given-names>J.-S.</given-names></name>
<etal/>
</person-group><article-title>Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer</article-title><source>N. Engl. J. Med.</source><year>2023</year><volume>389</volume><fpage>2063</fpage><lpage>2075</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2307980</pub-id><pub-id pub-id-type="pmid">37861218</pub-id>
</element-citation></ref><ref id="B85-vaccines-13-00185"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gadgeel</surname><given-names>S.M.</given-names></name>
</person-group><article-title>Targeted Therapy and Immune Therapy for Small Cell Lung Cancer</article-title><source>Curr. Treat. Options Oncol.</source><year>2018</year><volume>19</volume><fpage>53</fpage><pub-id pub-id-type="doi">10.1007/s11864-018-0568-3</pub-id><pub-id pub-id-type="pmid">30203184</pub-id>
</element-citation></ref><ref id="B86-vaccines-13-00185"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Krug</surname><given-names>L.M.</given-names></name>
</person-group><article-title>Vaccine Therapy for Small Cell Lung Cancer</article-title><source>Semin. Oncol.</source><year>2004</year><volume>31</volume><issue>(Suppl. S1)</issue><fpage>112</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1053/j.seminoncol.2003.12.022</pub-id><pub-id pub-id-type="pmid">14981589</pub-id>
</element-citation></ref><ref id="B87-vaccines-13-00185"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pettenati</surname><given-names>C.</given-names></name>
<name><surname>Ingersoll</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Mechanisms of BCG Immunotherapy and Its Outlook for Bladder Cancer</article-title><source>Nat. Rev. Urol.</source><year>2018</year><volume>15</volume><fpage>615</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1038/s41585-018-0055-4</pub-id><pub-id pub-id-type="pmid">29991725</pub-id>
</element-citation></ref><ref id="B88-vaccines-13-00185"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sfakianos</surname><given-names>J.P.</given-names></name>
<name><surname>Salome</surname><given-names>B.</given-names></name>
<name><surname>Daza</surname><given-names>J.</given-names></name>
<name><surname>Farkas</surname><given-names>A.</given-names></name>
<name><surname>Bhardwaj</surname><given-names>N.</given-names></name>
<name><surname>Horowitz</surname><given-names>A.</given-names></name>
</person-group><article-title>Bacillus Calmette-Guerin (BCG): Its Fight against Pathogens and Cancer</article-title><source>Urol. Oncol. Semin. Orig. Investig.</source><year>2021</year><volume>39</volume><fpage>121</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.urolonc.2020.09.031</pub-id></element-citation></ref><ref id="B89-vaccines-13-00185"><label>89.</label><element-citation publication-type="gov"><article-title>Study Details|Monoclonal Antibody Therapy Plus BCG in Treating Patients with Limited-Stage Small Cell Lung Cancer|ClinicalTrials.gov</article-title><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT00006352?cond=NCT00006352&#x00026;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT00006352?cond=NCT00006352&#x00026;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-21">(accessed on 21 December 2024)</date-in-citation></element-citation></ref><ref id="B90-vaccines-13-00185"><label>90.</label><element-citation publication-type="gov"><article-title>Study Details|Survival in a Randomized Phase III Trial in Patients with Limited Disease (LD) Small Cell Lung Cancer Vaccinated with Adjuvant BEC2 and BCG|ClinicalTrials.gov</article-title><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT00037713?cond=NCT00037713&#x00026;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT00037713?cond=NCT00037713&#x00026;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-21">(accessed on 21 December 2024)</date-in-citation></element-citation></ref><ref id="B91-vaccines-13-00185"><label>91.</label><element-citation publication-type="gov"><article-title>Study Details|Vaccination Therapy in Treating Patients with Limited-Stage Small Cell Lung Cancer|ClinicalTrials.gov</article-title><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT00003279?cond=NCT00003279&#x00026;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT00003279?cond=NCT00003279&#x00026;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-21">(accessed on 21 December 2024)</date-in-citation></element-citation></ref><ref id="B92-vaccines-13-00185"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>H.</given-names></name>
<name><surname>Jiang</surname><given-names>Z.</given-names></name>
</person-group><article-title>Advances in Antibody Therapeutics Targeting Small-Cell Lung Cancer</article-title><source>Adv. Clin. Exp. Med.</source><year>2018</year><volume>27</volume><fpage>1317</fpage><lpage>1323</lpage><pub-id pub-id-type="doi">10.17219/acem/70159</pub-id><pub-id pub-id-type="pmid">29790694</pub-id>
</element-citation></ref><ref id="B93-vaccines-13-00185"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bottomley</surname><given-names>A.</given-names></name>
<name><surname>Debruyne</surname><given-names>C.</given-names></name>
<name><surname>Felip</surname><given-names>E.</given-names></name>
<name><surname>Millward</surname><given-names>M.</given-names></name>
<name><surname>Thiberville</surname><given-names>L.</given-names></name>
<name><surname>Addario</surname><given-names>G.D.</given-names></name>
<name><surname>Rome</surname><given-names>L.</given-names></name>
<name><surname>Zatloukal</surname><given-names>P.</given-names></name>
<name><surname>Coens</surname><given-names>C.</given-names></name>
<name><surname>Giaccone</surname><given-names>G.</given-names></name>
</person-group><article-title>Symptom and Quality of Life Results of an International Randomised Phase III Study of Adjuvant Vaccination with Bec2/BCG in Responding Patients with Limited Disease Small-Cell Lung Cancer</article-title><source>Eur. J. Cancer</source><year>2008</year><volume>44</volume><fpage>2178</fpage><lpage>2184</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2008.06.036</pub-id><pub-id pub-id-type="pmid">18676140</pub-id>
</element-citation></ref><ref id="B94-vaccines-13-00185"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Giaccone</surname><given-names>G.</given-names></name>
<name><surname>Debruyne</surname><given-names>C.</given-names></name>
<name><surname>Felip</surname><given-names>E.</given-names></name>
<name><surname>Chapman</surname><given-names>P.B.</given-names></name>
<name><surname>Grant</surname><given-names>S.C.</given-names></name>
<name><surname>Millward</surname><given-names>M.</given-names></name>
<name><surname>Thiberville</surname><given-names>L.</given-names></name>
<name><surname>D&#x02019;Addario</surname><given-names>G.</given-names></name>
<name><surname>Coens</surname><given-names>C.</given-names></name>
<name><surname>Rome</surname><given-names>L.S.</given-names></name>
<etal/>
</person-group><article-title>Phase III Study of Adjuvant Vaccination with Bec2/Bacille Calmette-Guerin in Responding Patients with Limited-Disease Small-Cell Lung Cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study)</article-title><source>J. Clin. Oncol.</source><year>2005</year><volume>23</volume><fpage>6854</fpage><lpage>6864</lpage><comment>Available online: <ext-link xlink:href="https://ascopubs.org/doi/abs/10.1200/jco.2005.17.186" ext-link-type="uri">https://ascopubs.org/doi/abs/10.1200/jco.2005.17.186</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-11">(accessed on 11 December 2024)</date-in-citation><pub-id pub-id-type="doi">10.1200/JCO.2005.17.186</pub-id><pub-id pub-id-type="pmid">16192577</pub-id>
</element-citation></ref><ref id="B95-vaccines-13-00185"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feng</surname><given-names>D.</given-names></name>
<name><surname>Shaikh</surname><given-names>A.S.</given-names></name>
<name><surname>Wang</surname><given-names>F.</given-names></name>
</person-group><article-title>Recent Advance in Tumor-Associated Carbohydrate Antigens (TACAs)-Based Antitumor Vaccines</article-title><source>ACS Chem. Biol.</source><year>2016</year><volume>11</volume><fpage>850</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1021/acschembio.6b00084</pub-id><pub-id pub-id-type="pmid">26895482</pub-id>
</element-citation></ref><ref id="B96-vaccines-13-00185"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hossain</surname><given-names>F.</given-names></name>
<name><surname>Andreana</surname><given-names>P.R.</given-names></name>
</person-group><article-title>Developments in Carbohydrate-Based Cancer Therapeutics</article-title><source>Pharmaceuticals</source><year>2019</year><volume>12</volume><elocation-id>84</elocation-id><pub-id pub-id-type="doi">10.3390/ph12020084</pub-id><pub-id pub-id-type="pmid">31167407</pub-id>
</element-citation></ref><ref id="B97-vaccines-13-00185"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Berois</surname><given-names>N.</given-names></name>
<name><surname>Pittini</surname><given-names>A.</given-names></name>
<name><surname>Osinaga</surname><given-names>E.</given-names></name>
</person-group><article-title>Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives</article-title><source>Cancers</source><year>2022</year><volume>14</volume><elocation-id>645</elocation-id><pub-id pub-id-type="doi">10.3390/cancers14030645</pub-id><pub-id pub-id-type="pmid">35158915</pub-id>
</element-citation></ref><ref id="B98-vaccines-13-00185"><label>98.</label><element-citation publication-type="gov"><article-title>Definition of Pentavalent KLH Conjugate Vaccine&#x02014;NCI Drug Dictionary&#x02014;NCI</article-title><comment>Available online: <ext-link xlink:href="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pentavalent-klh-conjugate-vaccine" ext-link-type="uri">https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pentavalent-klh-conjugate-vaccine</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-12">(accessed on 12 December 2024)</date-in-citation></element-citation></ref><ref id="B99-vaccines-13-00185"><label>99.</label><element-citation publication-type="gov"><article-title>Study Details|Immunization with a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid|ClinicalTrials.gov</article-title><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT01349647?cond=fucosyl&#x00026;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT01349647?cond=fucosyl&#x00026;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-12">(accessed on 12 December 2024)</date-in-citation></element-citation></ref><ref id="B100-vaccines-13-00185"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elwakeel</surname><given-names>A.</given-names></name>
<name><surname>Bridgewater</surname><given-names>H.E.</given-names></name>
<name><surname>Bennett</surname><given-names>J.</given-names></name>
</person-group><article-title>Unlocking Dendritic Cell-Based Vaccine Efficacy through Genetic Modulation&#x02014;How Soon Is Now?</article-title><source>Genes</source><year>2023</year><volume>14</volume><elocation-id>2118</elocation-id><pub-id pub-id-type="doi">10.3390/genes14122118</pub-id><pub-id pub-id-type="pmid">38136940</pub-id>
</element-citation></ref><ref id="B101-vaccines-13-00185"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>DeLeo</surname><given-names>A.B.</given-names></name>
<name><surname>Appella</surname><given-names>E.</given-names></name>
</person-group><article-title>The P53 Saga: Early Steps in the Development of Tumor Immunotherapy</article-title><source>J. Immunol.</source><year>2020</year><volume>204</volume><fpage>2321</fpage><lpage>2328</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1901343</pub-id><pub-id pub-id-type="pmid">32312843</pub-id>
</element-citation></ref><ref id="B102-vaccines-13-00185"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lane</surname><given-names>D.P.</given-names></name>
<name><surname>Cheok</surname><given-names>C.F.</given-names></name>
<name><surname>Lain</surname><given-names>S.</given-names></name>
</person-group><article-title>P53-Based Cancer Therapy</article-title><source>Cold Spring Harb. Perspect. Biol.</source><year>2010</year><volume>2</volume><elocation-id>a001222</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a001222</pub-id><pub-id pub-id-type="pmid">20463003</pub-id>
</element-citation></ref><ref id="B103-vaccines-13-00185"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carlsen</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>S.</given-names></name>
<name><surname>Tian</surname><given-names>X.</given-names></name>
<name><surname>De La Cruz</surname><given-names>A.</given-names></name>
<name><surname>George</surname><given-names>A.</given-names></name>
<name><surname>Arnoff</surname><given-names>T.E.</given-names></name>
<name><surname>El-Deiry</surname><given-names>W.S.</given-names></name>
</person-group><article-title>The Role of P53 in Anti-Tumor Immunity and Response to Immunotherapy</article-title><source>Front. Mol. Biosci.</source><year>2023</year><volume>10</volume><elocation-id>1148389</elocation-id><pub-id pub-id-type="doi">10.3389/fmolb.2023.1148389</pub-id><pub-id pub-id-type="pmid">37602328</pub-id>
</element-citation></ref><ref id="B104-vaccines-13-00185"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Simanshu</surname><given-names>D.K.</given-names></name>
<name><surname>Nissley</surname><given-names>D.V.</given-names></name>
<name><surname>McCormick</surname><given-names>F.</given-names></name>
</person-group><article-title>RAS Proteins and Their Regulators in Human Disease</article-title><source>Cell</source><year>2017</year><volume>170</volume><fpage>17</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.06.009</pub-id><pub-id pub-id-type="pmid">28666118</pub-id>
</element-citation></ref><ref id="B105-vaccines-13-00185"><label>105.</label><element-citation publication-type="gov"><article-title>Definition of Ras Peptide Cancer Vaccine&#x02014;NCI Drug Dictionary&#x02014;NCI</article-title><comment>Available online: <ext-link xlink:href="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ras-peptide-cancer-vaccine" ext-link-type="uri">https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ras-peptide-cancer-vaccine</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-13">(accessed on 13 December 2024)</date-in-citation></element-citation></ref><ref id="B106-vaccines-13-00185"><label>106.</label><element-citation publication-type="gov"><article-title>Study Details|Vaccine Therapy and Biological Therapy in Treating Patients with Advanced Cancer|ClinicalTrials.gov</article-title><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT00019084?cond=p53%20vaccine%C2%A0&#x00026;rank=9" ext-link-type="uri">https://clinicaltrials.gov/study/NCT00019084?cond=p53%20vaccine%C2%A0&#x00026;rank=9</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-13">(accessed on 13 December 2024)</date-in-citation></element-citation></ref><ref id="B107-vaccines-13-00185"><label>107.</label><element-citation publication-type="gov"><article-title>Definition of Interleukin-2&#x02014;NCI Dictionary of Cancer Terms&#x02014;NCI</article-title><comment>Available online: <ext-link xlink:href="https://www.cancer.gov/publications/dictionaries/cancer-terms/def/interleukin-2" ext-link-type="uri">https://www.cancer.gov/publications/dictionaries/cancer-terms/def/interleukin-2</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-13">(accessed on 13 December 2024)</date-in-citation></element-citation></ref><ref id="B108-vaccines-13-00185"><label>108.</label><element-citation publication-type="gov"><article-title>Definition of Adenovirus-p53 Transduced Dendritic Cell Vaccine&#x02014;NCI Drug Dictionary&#x02014;NCI</article-title><comment>Available online: <ext-link xlink:href="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/adenovirus-p53-transduced-dendritic-cell-vaccine" ext-link-type="uri">https://www.cancer.gov/publications/dictionaries/cancer-drug/def/adenovirus-p53-transduced-dendritic-cell-vaccine</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-13">(accessed on 13 December 2024)</date-in-citation></element-citation></ref><ref id="B109-vaccines-13-00185"><label>109.</label><element-citation publication-type="gov"><article-title>Study Details|Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac&#x02014;Patients with Small Cell Lung Cancer (SCLC)|ClinicalTrials.gov</article-title><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT03406715?cond=NCT03406715&#x00026;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT03406715?cond=NCT03406715&#x00026;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-13">(accessed on 13 December 2024)</date-in-citation></element-citation></ref><ref id="B110-vaccines-13-00185"><label>110.</label><element-citation publication-type="gov"><article-title>Study Details|Chemotherapy Followed by Vaccine Therapy in Treating Patients with Extensive-Stage Small Cell Lung Cancer|ClinicalTrials.gov</article-title><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT00049218?cond=p53%20vaccine%C2%A0&#x00026;rank=12" ext-link-type="uri">https://clinicaltrials.gov/study/NCT00049218?cond=p53%20vaccine%C2%A0&#x00026;rank=12</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-13">(accessed on 13 December 2024)</date-in-citation></element-citation></ref><ref id="B111-vaccines-13-00185"><label>111.</label><element-citation publication-type="gov"><article-title>Study Details|To Immunize Patients with Extensive Stage SCLC Combined with Chemo with or Without All Trans Retinoic Acid|ClinicalTrials.gov</article-title><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT00617409?cond=p53%20vaccine%C2%A0&#x00026;rank=16" ext-link-type="uri">https://clinicaltrials.gov/study/NCT00617409?cond=p53%20vaccine%C2%A0&#x00026;rank=16</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-13">(accessed on 13 December 2024)</date-in-citation></element-citation></ref><ref id="B112-vaccines-13-00185"><label>112.</label><element-citation publication-type="gov"><article-title>Definition of All-Trans Retinoic Acid&#x02014;NCI Dictionary of Cancer Terms&#x02014;NCI</article-title><comment>Available online: <ext-link xlink:href="https://www.cancer.gov/publications/dictionaries/cancer-terms/def/all-trans-retinoic-acid" ext-link-type="uri">https://www.cancer.gov/publications/dictionaries/cancer-terms/def/all-trans-retinoic-acid</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-13">(accessed on 13 December 2024)</date-in-citation></element-citation></ref><ref id="B113-vaccines-13-00185"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chiappori</surname><given-names>A.A.</given-names></name>
<name><surname>Soliman</surname><given-names>H.</given-names></name>
<name><surname>Janssen</surname><given-names>W.E.</given-names></name>
<name><surname>Antonia</surname><given-names>S.J.</given-names></name>
<name><surname>Gabrilovich</surname><given-names>D.I.</given-names></name>
</person-group><article-title>INGN-225: A Dendritic Cell-Based P53 Vaccine (Ad.P53-DC) in Small Cell Lung Cancer: Observed Association between Immune Response and Enhanced Chemotherapy Effect</article-title><source>Expert Opin. Biol. Ther.</source><year>2010</year><volume>10</volume><fpage>983</fpage><lpage>991</lpage><pub-id pub-id-type="doi">10.1517/14712598.2010.484801</pub-id><pub-id pub-id-type="pmid">20420527</pub-id>
</element-citation></ref><ref id="B114-vaccines-13-00185"><label>114.</label><element-citation publication-type="webpage"><article-title>New Report: Lung Cancer Survival Rate Improves, But Gaps in Biomarker Testing and Lack of Screening|American Lung Association</article-title><comment>Available online: <ext-link xlink:href="https://www.lung.org/media/press-releases/state-of-lung-cancer-2024" ext-link-type="uri">https://www.lung.org/media/press-releases/state-of-lung-cancer-2024</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-25">(accessed on 25 December 2024)</date-in-citation></element-citation></ref><ref id="B115-vaccines-13-00185"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Sousa</surname><given-names>L.G.</given-names></name>
<name><surname>Rajapakshe</surname><given-names>K.</given-names></name>
<name><surname>Rodriguez Canales</surname><given-names>J.</given-names></name>
<name><surname>Chin</surname><given-names>R.L.</given-names></name>
<name><surname>Feng</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>Q.</given-names></name>
<name><surname>Barrese</surname><given-names>T.Z.</given-names></name>
<name><surname>Massarelli</surname><given-names>E.</given-names></name>
<name><surname>William</surname><given-names>W.</given-names></name>
<name><surname>Johnson</surname><given-names>F.M.</given-names></name>
<etal/>
</person-group><article-title>ISA101 and Nivolumab for HPV-16+ Cancer: Updated Clinical Efficacy and Immune Correlates of Response</article-title><source>J. Immunother. Cancer</source><year>2022</year><volume>10</volume><fpage>e004232</fpage><pub-id pub-id-type="doi">10.1136/jitc-2021-004232</pub-id><pub-id pub-id-type="pmid">35193933</pub-id>
</element-citation></ref><ref id="B116-vaccines-13-00185"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>A.</given-names></name>
<name><surname>Dixit</surname><given-names>S.</given-names></name>
<name><surname>Srinivasan</surname><given-names>K.</given-names></name>
<name><surname>M</surname><given-names>D.</given-names></name>
<name><surname>Vincent</surname><given-names>P.M.D.R.</given-names></name>
</person-group><article-title>Personalized Cancer Vaccine Design Using AI-Powered Technologies</article-title><source>Front. Immunol.</source><year>2024</year><volume>15</volume><elocation-id>1357217</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2024.1357217</pub-id><pub-id pub-id-type="pmid">39582860</pub-id>
</element-citation></ref><ref id="B117-vaccines-13-00185"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feng</surname><given-names>T.</given-names></name>
<name><surname>Hu</surname><given-names>J.</given-names></name>
<name><surname>Wen</surname><given-names>J.</given-names></name>
<name><surname>Qian</surname><given-names>Z.</given-names></name>
<name><surname>Che</surname><given-names>G.</given-names></name>
<name><surname>Zhou</surname><given-names>Q.</given-names></name>
<name><surname>Zhu</surname><given-names>L.</given-names></name>
</person-group><article-title>Personalized Nanovaccines for Treating Solid Cancer Metastases</article-title><source>J. Hematol. Oncol.</source><year>2024</year><volume>17</volume><fpage>115</fpage><pub-id pub-id-type="doi">10.1186/s13045-024-01628-4</pub-id><pub-id pub-id-type="pmid">39609851</pub-id>
</element-citation></ref><ref id="B118-vaccines-13-00185"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kooreman</surname><given-names>N.G.</given-names></name>
<name><surname>Kim</surname><given-names>Y.</given-names></name>
<name><surname>de Almeida</surname><given-names>P.E.</given-names></name>
<name><surname>Termglinchan</surname><given-names>V.</given-names></name>
<name><surname>Diecke</surname><given-names>S.</given-names></name>
<name><surname>Shao</surname><given-names>N.Y.</given-names></name>
<name><surname>Wei</surname><given-names>T.T.</given-names></name>
<name><surname>Yi</surname><given-names>H.</given-names></name>
<name><surname>Dey</surname><given-names>D.</given-names></name>
<name><surname>Nelakanti</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Autologous IPSC-Based Vaccines Elicit Anti-Tumor Responses In Vivo</article-title><source>Cell Stem Cell</source><year>2018</year><volume>22</volume><fpage>501</fpage><lpage>513.e7</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2018.01.016</pub-id><pub-id pub-id-type="pmid">29456158</pub-id>
</element-citation></ref><ref id="B119-vaccines-13-00185"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ouyang</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Guo</surname><given-names>J.</given-names></name>
<name><surname>Wei</surname><given-names>T.T.</given-names></name>
<name><surname>Liu</surname><given-names>C.</given-names></name>
<name><surname>Lee</surname><given-names>B.</given-names></name>
<name><surname>Chen</surname><given-names>B.</given-names></name>
<name><surname>Zhang</surname><given-names>A.</given-names></name>
<name><surname>Casey</surname><given-names>K.M.</given-names></name>
<etal/>
</person-group><article-title>Antitumor Effects of IPSC-Based Cancer Vaccine in Pancreatic Cancer</article-title><source>Stem Cell Rep.</source><year>2021</year><volume>16</volume><fpage>1468</fpage><lpage>1477</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2021.04.004</pub-id><pub-id pub-id-type="pmid">33961792</pub-id>
</element-citation></ref><ref id="B120-vaccines-13-00185"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meng</surname><given-names>S.</given-names></name>
<name><surname>Whitt</surname><given-names>A.G.</given-names></name>
<name><surname>Stamp</surname><given-names>B.F.</given-names></name>
<name><surname>Eaton</surname><given-names>J.W.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Yaddanapudi</surname><given-names>K.</given-names></name>
</person-group><article-title>Exosome-Based Cancer Vaccine for Prevention of Lung Cancer</article-title><source>Stem Cell Investig.</source><year>2023</year><volume>10</volume><fpage>2</fpage><pub-id pub-id-type="doi">10.21037/sci-2022-030</pub-id><pub-id pub-id-type="pmid">36742283</pub-id>
</element-citation></ref><ref id="B121-vaccines-13-00185"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meng</surname><given-names>S.</given-names></name>
<name><surname>Whitt</surname><given-names>A.G.</given-names></name>
<name><surname>Eaton</surname><given-names>J.W.</given-names></name>
<name><surname>Yaddanapudi</surname><given-names>K.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
</person-group><article-title>The Efficacy of an Embryonic Stem Cell-Based Vaccine for Lung Cancer Prevention Depends on the Undifferentiated State of the Stem Cells</article-title><source>Sci. Rep.</source><year>2024</year><volume>14</volume><elocation-id>32127</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-024-83932-0</pub-id><pub-id pub-id-type="pmid">39739089</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-13-00185-f001"><label>Figure 1</label><caption><p>Mechanism of action of tumor peptide vaccines. MHC I: Major histocompatibility complex I, MHC II: Major histocompatibility complex II. Created in BioRender. Gangane, S. (2025) <uri xlink:href="https://BioRender.com/h94t084">https://BioRender.com/h94t084</uri> (accessed on 30 January 2025).</p></caption><graphic xlink:href="vaccines-13-00185-g001" position="float"/></fig><fig position="float" id="vaccines-13-00185-f002"><label>Figure 2</label><caption><p>Mechanism of action of tumor DNA vaccines. MHC I, MHC II, APC: Antigen-presenting cell. Created in BioRender. Gangane, S. (2025) <uri xlink:href="https://BioRender.com/y82k991">https://BioRender.com/y82k991</uri> (accessed on 30 January 2025).</p></caption><graphic xlink:href="vaccines-13-00185-g002" position="float"/></fig><fig position="float" id="vaccines-13-00185-f003"><label>Figure 3</label><caption><p>Mechanism of action of vector vaccines. MHC I, MHC II, APC. Created in BioRender. Gangane, S. (2025) <uri xlink:href="https://BioRender.com/e73e024">https://BioRender.com/e73e024</uri> (accessed on 30 January 2025).</p></caption><graphic xlink:href="vaccines-13-00185-g003" position="float"/></fig><fig position="float" id="vaccines-13-00185-f004"><label>Figure 4</label><caption><p>Mechanism of action of dendritic cell vaccines. MHC I, MHC II, TNF-&#x003b1;: Tumor necrosis factor alpha, IL-12: Interleukin 12, IL-23: Interleukin 23, TCR: T-cell receptor, CTL: cytotoxic T-lymphocyte. Citation: Created in BioRender. Raza, F. (2025) <uri xlink:href="https://BioRender.com/c23d034">https://BioRender.com/c23d034</uri> (accessed on 31 January 2025).</p></caption><graphic xlink:href="vaccines-13-00185-g004" position="float"/></fig><fig position="float" id="vaccines-13-00185-f005"><label>Figure 5</label><caption><p>Mechanism of action of allogenic vaccines. MHC I, TCR, CTL. Citation: Created in BioRender. Raza, F. (2025) <uri xlink:href="https://BioRender.com/c23d034">https://BioRender.com/c23d034</uri> (accessed on 31 January 2025).</p></caption><graphic xlink:href="vaccines-13-00185-g005" position="float"/></fig><fig position="float" id="vaccines-13-00185-f006"><label>Figure 6</label><caption><p>Mechanism of action mRNA vaccines. Citation: Created in BioRender. Raza, F. (2025) <uri xlink:href="https://BioRender.com/c23d034">https://BioRender.com/c23d034</uri> (accessed on 30 January 2025).</p></caption><graphic xlink:href="vaccines-13-00185-g006" position="float"/></fig><table-wrap position="float" id="vaccines-13-00185-t001"><object-id pub-id-type="pii">vaccines-13-00185-t001_Table 1</object-id><label>Table 1</label><caption><p>Previous and ongoing clinical trials with peptide vaccines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Name (Clinical Trial)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phase</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Stage</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Side Effects</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Results</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CIMAvax-EGF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Longitudinal study conducted in a real-world setting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IIIB/IV NSCLC with partial response or stable disease after first-line chemotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Injection site pain, local erythema, nausea, dizziness, and fever</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary endpoints<break/>- OS 14.6 months (95% CI 4.9&#x02013;11.3)<break/>- PFS 8.16 months (95% CI 4.9&#x02013;11.3)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CIMAvax-EGF in combination with nivolumab <break/>(NCT02955290)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Late-stage disease requiring systemic therapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Information not published</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary endpoint<break/>- OS 11.9 months (90% CI 8.0&#x02013;23.9)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MAGE-A3<break/>(NCT00480025-MAGRIT study)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MAGE-A3 positive resected IB, II, or IIIA NSCLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Information not published</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study was terminated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LV305 <break/>(NCT02122861)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Locally advanced, relapsed, or metastatic cancers expressing NY-ESO-1 (&#x02265;5% of expression)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fatigue, injection site reactions, and myalgia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Only one patient with NSCLC enrolled.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tecemotide <break/>(NCT01731587)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unresectable stage III NSCLC with stable disease after primary chemo-radiotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial withdrawn</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical trial withdrawn</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tecemotide in addition to bevacizumab as a maintenance therapy <break/>(NCT00828009)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IIB</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unresectable Stage IIIA and IIIB Non-Squamous NSCLC after definitive chemoradiation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anemia, heart failure, pericardial effusion, esophageal ulcer, hemorrhoidal hemorrhage, sepsis, UTI, transaminitis, lymphopenia, weight loss, hypertension, and thromboembolic events</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary endpoint <break/>- Safety and tolerability<break/>Outcomes<break/>- OS 42.7 months (95% CI 21.7&#x02013;63.3)<break/>- PFS 14.9 months (95% CI 11.0&#x02013;20.9)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tecemotide<break/>(NCT00409188&#x02014;START trial)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unresectable stage III NSCLC who has completed chemoradiation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dyspnea, metastases to central nervous system, and pneumonia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary endpoint<break/>- No change in median OS 25.6 months (95% CI 22.5&#x02013;29.2) in the tecemotide group versus 22.3 months (95% 19.6&#x02013;25.5) in the placebo group</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tecemotide<break/>(NCT02049151&#x02014;START2 trial)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unresectable stage III NSCLC receiving concurrent chemoradiation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Information not published</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study was terminated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tecemotide<break/>(NCT01015443&#x02014;INSPIRE trial)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unresectable stage III NSCLC in the Asian population</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Information not published</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study was terminated</td></tr></tbody></table><table-wrap-foot><fn><p>OS: Overall survival, PFS: Progression-free survival.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-13-00185-t002"><object-id pub-id-type="pii">vaccines-13-00185-t002_Table 2</object-id><label>Table 2</label><caption><p>Vector vaccine clinical trials.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Name (Clinical Trial)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phase</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Stage</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Side Effects</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Results</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">First-line chemotherapy combined with TG4010 and nivolumab<break/>(NCT03353675)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced stage and immunotherapy-naive non-squamous NSCLS and with &#x0003c;50% of tumor cells expressing PD-L1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Information not published</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pending</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TG4010 in association with chemotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage IIIB and IV NSCLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fatigue, injection site reactions, injection site pain, pyrexia, and fever</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary endpoint<break/>- Arm 1 PR was observed in 13/37 patients by RECIST criteria.<break/>- Arm 2 did not meet criteria for PR</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">New vaccine semi-allogeneic fibroblasts transfected with autologous tumor-derived DNA<break/>(NCT00793208)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Information not published</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study closed due to low enrollment.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MG1-MAGEA3 with Ad-MAGEA3 Vaccine in combination with pembrolizumab<break/>(NCT02879760)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I/II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC patients who have completed a first standard therapy with at least 1 cycle of chemotherapy and/or at least one treatment of PD-1 or PDL-1 antibody targeted therapy.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Information not published</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pending</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MG1 Maraba/MAGE-A3, with and without adenovirus vaccine with transgenic MAGE-A3 insertion<break/>(NCT02285816)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Incurable advanced/metastatic MAGE-A3-expressing solid tumors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Information not published</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pending</td></tr></tbody></table><table-wrap-foot><fn><p>PR: Partial response.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-13-00185-t003"><object-id pub-id-type="pii">vaccines-13-00185-t003_Table 3</object-id><label>Table 3</label><caption><p>Dendritic cell vaccine clinical trials.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Name (Clinical Trial)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phase</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Stage</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Side Effects</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Results</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AdCCL21-DC<break/>(NCT00601094)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage IIIB, stage IV, or recurrent NSCLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Information not published</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pending</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AdCCL21-DC<break/>(NCT01574222)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage IIIB, stage IV NSCLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flu-like symptoms, nausea, and fatigue</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary endpoint<break/>- Safety <break/>- Manageable adverse events <break/>- Systemic immune response in 6/16 patients</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AdCCL21-DC in combination with pembrolizumab <break/>(NCT03546361)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stage IV NSCLC patients who are either EGFR/ALK wild-type after progression on a PD-L1 inhibitor or EGFR/ALK mutant after progression on TKI therapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Information not published</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pending</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-13-00185-t004"><object-id pub-id-type="pii">vaccines-13-00185-t004_Table 4</object-id><label>Table 4</label><caption><p>Allogenic cell vaccine clinical trials.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Name (Clinical Trial)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phase</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Stage</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Side Effects</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Results</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Belagenpumatucel-L<break/>(NCT00676507&#x02014;STOP trial)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III/IV NSCLC patients who had no disease progression after first-line chemotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Injection site reactions, cough, and fatigue</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The study failed primary endpoint in median OS, 20.3 (95% CI, 16.8&#x02013;23.7) for vaccinated group and 17.8 months (95% CI, 13.7&#x02013;22.0) for placebo group.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GM.CD40L bystander cells admixed with an equivalent number of the 2 allogeneic tumor cell lines, NCI-H1944, NCI-H2122 in combination with cyclophosphamide and tretinoin <break/>(NCT00601796)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IIIB and IV lung adenocarcinoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Headache, injection site reaction, and fatigue.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The study failed primary endpoint of inducing radiologic tumor regression even in patients with an immune response to vaccination.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tergenpumatucel-L<break/>(NCT02460367)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ib/2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Previously treated NSCLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Information not published</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study was terminated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tergenpumatucel-L<break/>(NCT01774578)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2B</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced NSCLC previously undergone surgery, radiotherapy, and &#x02264;2 prior chemotherapy regimens for this diagnosis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Information not published</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pending</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viagenpumatucel-L in combination with nivolumab <break/>(NCT02439450&#x02014;DURGA trial)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ib/2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced NSCLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fatigue, cough, and diarrhea</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary endpoint<break/>- Combination is safe</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-13-00185-t005"><object-id pub-id-type="pii">vaccines-13-00185-t005_Table 5</object-id><label>Table 5</label><caption><p>mRNA vaccine clinical trials.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Name (Clinical Trial)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phase</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Stage</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Side Effects</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Results</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BNT116 in addition to docetaxel <break/>(NCT05142189&#x02014;LuCa-MERIT-1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced NSCLC, PD-L1 expression &#x02265; 50%, disease progression on or after anti-PD-L1 therapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neutropenia, pneumonia, hypertension, leukopenia, and fatigue, BNT166-related adverse events (cytokine release syndrome, bronchospasm, pyrexia)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preliminary results<break/>- 7/20 PR and 10/20 SD by RECIST v1.1 criteria</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V940 + pembrolizumab<break/>(NCT06623422)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Resectable stage II to IIIB (N2) NSCLC not achieving pCR after receiving neoadjuvant pembrolizumab with platinum-based doublet chemotherapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Information not published</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pending</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V940 + pembrolizumab<break/>(NCT06077760)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed resected stage II, IIIA, IIIB (with nodal involvement, N2) NSCLC.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Information not published</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pending</td></tr></tbody></table><table-wrap-foot><fn><p>SD: Stable disease.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-13-00185-t006"><object-id pub-id-type="pii">vaccines-13-00185-t006_Table 6</object-id><label>Table 6</label><caption><p>SCLC vaccine clinical trials.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Name (Clinical Trial)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phase</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Stage</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Side Effects</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Results</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monoclonal antibody BEC2 and BCG<break/>(NCT00003279, NCT00037713, NCT00006352 &#x02013;Silva study)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">III</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Survival patients with limited disease SCLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Skin ulcerations, and mild flu-like symptoms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">There was no improvement in median OS (16.4 and 14.3 months <italic toggle="yes">p</italic> = 0.28), progression-free survival, or quality of life.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pentavalent vaccine composed of KLH-conjugates of GD2L, GD3L, globo H, fucosyl GM1, and N-propionylated polysialic acid <break/>(NCT01349647)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Information not published</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pending</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antigen-presenting cells pulsed in vitro with synthetic peptide corresponding to the tumor&#x02019;s p53 or RAS mutation<break/>(NCT00019084 )</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patients with advanced cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Information not published</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pending</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ad.p53-DC in combination with nivolumab and ipilimumab <break/>(NCT03406715)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SCLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Information not published</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pending</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dendritic cell-adenovirus p53 vaccine <break/>(NCT00049218&#x02014;INGN-225 Trial)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I/II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Extensive-stage SCLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Injections site erythema, fatigue, arthralgia, and myalgias</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary endpoints<break/>- Safety and immune response <break/>- Clinical response <break/>- Correlation with immune response</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dendritic cell-adenovirus p53 vaccine in combination with chemotherapy with or without all trans retinoic acid <break/>(NCT00617409)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Extensive-stage SCLC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Information not published</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pending</td></tr></tbody></table></table-wrap></floats-group></article>